10636001RTR

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS 15	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 16	FEB 22	Status of current WO (PCT) information on STN
NEWS 17	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 18	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 19	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 20	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 21	FEB 28	TOXCENTER reloaded with enhancements
NEWS 22	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 23	MAR 01	INSPEC reloaded and enhanced

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:52:27 ON 01 MAR 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 16:53:57 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0
DICTIONARY FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10636001Exp2.str





10636001RTR

chain nodes :
1 2 3 4 5 6 7
chain bonds :
1-2 2-3 3-4 3-7 4-5 4-6
exact/norm bonds :
3-4 3-7 4-5 4-6
exact bonds :
1-2 2-3

G1:H,CH3

Match level :
1:Atom 2:Atom 3:CLASS 4:CLASS 5:Atom 6:CLASS 7:CLASS
Generic attributes :
1:
Saturation : Unsaturated
2:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:54:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 397171 TO ITERATE

0.5% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 7907414 TO 7979426
PROJECTED ANSWERS: 6748 TO 9138

L2 2 SEA SSS SAM L1

10636001RTR

=>
Uploading C:\Program Files\Stnexp\Queries\10636001exp21.str





chain nodes :
1 2 3 4 5 6 7
chain bonds :
1-2 2-3 3-4 3-7 4-5 4-6
exact/norm bonds :
3-4 3-7 4-5 4-6
exact bonds :
1-2 2-3

G1:H,CH3

Match level :
1:Atom 2:Atom 3:CLASS 4:CLASS 5:Atom 6:CLASS 7:CLASS
Generic attributes :
1:
Saturation : Unsaturated
2:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l3
SAMPLE SEARCH INITIATED 16:55:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 397171 TO ITERATE

0.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

10636001RTR

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 7907414 TO 7979426
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=>
Uploading C:\Program Files\Stnexp\Queries\10636001exp3.str





chain nodes :
1 2 3 4 5 10
ring nodes :
7 8 9
chain bonds :
1-5 1-2 1-7 2-3 2-4 8-10
ring bonds :
7-8 7-9 8-9
exact/norm bonds :
1-5 1-2 1-7 2-3 2-4 7-8 7-9 8-9
exact bonds :
8-10

G1:H,CH3

Match level :
1:CLASS 2:CLASS 3:Atom 4:CLASS 5:CLASS 7:Atom 8:CLASS 9:Atom 10:Atom

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l5

10636001RTR

SAMPLE SEARCH INITIATED 16:57:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 140936 TO ITERATE

1.4% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2796571 TO 2840869
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=>
Uploading C:\Program Files\Stnexp\Queries\10636001exp4.str



chain nodes :
1 2 3 4 5
ring nodes :
7 8 9 10 11 12 13 14 15
chain bonds :
1-5 1-2 1-7 2-3 2-4 8-10
ring bonds :
7-8 7-9 8-9 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
1-5 1-2 1-7 2-3 2-4 7-8 7-9 8-9
exact bonds :
8-10
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15

G1:H,CH3

Match level :
1:CLASS 2:CLASS 3:Atom 4:CLASS 5:CLASS 7:Atom 8:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom
Generic attributes :
3:
Saturation : Unsaturated
Type of Ring System : Monocyclic

L7 STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7 STR

10636001RTR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l7
SAMPLE SEARCH INITIATED 16:59:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 270 TO ITERATE

100.0% PROCESSED 270 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4415 TO 6385
PROJECTED ANSWERS: 2 TO 124

L8 2 SEA SSS SAM L7

=> s l7 full
FULL SEARCH INITIATED 16:59:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5421 TO ITERATE

100.0% PROCESSED 5421 ITERATIONS 71 ANSWERS
SEARCH TIME: 00.00.01

L9 71 SEA SSS FUL L7

=> fil hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	170.90	171.53

FILE 'HCAPLUS' ENTERED AT 16:59:59 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Mar 2006 VOL 144 ISS 10
FILE LAST UPDATED: 28 Feb 2006 (20060228/ED)

15 of 20

10636001RTR

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l9
L10 41 L9

=> d ed abs ibib hitstr 1-41

L10 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 03 Feb 2006
AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.
ACCESSION NUMBER: 2006:100738 HCAPLUS
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006024365	A1	20060202	US 2005-134633		20050519
US 2004096499	A1	20040520	US 2003-630446		20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	A	20020805
			IN 2002-MU699	A	20020805
			IN 2003-MU80	A	20030122
			IN 2003-MU82	A	20030122
			US 2003-630446	A2	20030729

IT 2829-19-8, Rolicyprine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)
RN 2829-19-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 10 Jan 2006
AB A theor. model has been developed that discriminates between active and nonactive drugs against HIV-1 with four different mechanisms of action for the active drugs. The model was built up using a probabilistic neural network (PNN) algorithm and a database of 2720 compds. The model showed an overall accuracy of 97.34% in the training series, 85.12% in the selection series, and 84.78% in an external prediction series. The model not only correctly classified a very heterogeneous series of organic compds. but also discriminated between very similar active/nonactive chems. that belong to the same family of compds. More specifically, the model recognized 96.02% of nonactive compds., 94.24% of active compds. that inhibited reverse transcriptase, 97.24% of protease inhibitors, 97.14% of virus uncoating inhibitors, and 90.32% of integrase inhibitors. The results indicate that this approach may represent a powerful tool for modeling large databases in QSAR with applications in medicinal chemical
ACCESSION NUMBER: 2006:44967 HCAPLUS
TITLE: Probabilistic Neural Network Model for the In Silico Evaluation of Anti-HIV Activity and Mechanism of Action
AUTHOR(S): Vilar, Santiago; Santana, Lourdes; Uriarte, Eugenio
CORPORATE SOURCE: Faculty of Pharmacy, Department of Organic Chemistry, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain
SOURCE: Journal of Medicinal Chemistry (2006), 49(3), 1118-1124
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT INDEXING IN PROGRESS
IT 2829-19-8, Rolicyprine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(probabilistic neural network model for In silico evaluation of anti-HIV activity and mechanism of action)
RN 2829-19-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 09 Dec 2005
GI



I



II

AB Title compds. I [R1 = H, alkyl, cycloalkyl; R2, R3 and R5 independently = H or halo; R4 = H, halo, alkyl, etc.; A = substituted oxazolyl, imidazole, thiazole or pyrrole], and their pharmaceutically acceptable salts, are prepared and disclosed as pde4 inhibitors. Thus, e.g., II was prepared in a multistep synthesis from 2-trifluoromethyl-8-methoxyquinolin-5-yl carboxylic acid. In PDE4 assays, selected compds. possessed IC50 values ranging from 0.01-1.8 nM. Also claimed are pharmaceutical compns., the use of the compds. as PDE4 inhibitors, and combinations with other actives.
ACCESSION NUMBER: 2005:1289687 HCAPLUS
DOCUMENT NUMBER: 144:51568
TITLE: Preparation of substituted 2-quinolyl-oxazoles and their heterocyclic analogs useful as pde4 inhibitors
INVENTOR(S): Huang, Rongze; Blythin, David; Shih, Neng-Yang; Shue, Ho-Jane; Chen, Xiao; Cao, Jianhua; Gu, Danlin; Huang, Ying; Schwerdt, John H.; Ting, Pauline C.; Wong, Shing-Chun; Xiao, Li
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 233 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116009	A1	20051208	WO 2005-US17134	20050516

L10 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2004-572266P P 20040518
IT 871007-61-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted quinolyloxazoles and their heterocyclic analogs useful as PDE4 inhibitors)
RN 871007-61-3 HCAPLUS
CN 4-Oxazolecarboxamide, 5-[(1S)-1-aminoethyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinolinyl]-N-[(1R,2S)-2-phenylcyclopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 10 Nov 2005
GI



AB IKK-2-inhibiting substituted thiophene amide compds. (shown as I and II (addnl. related Markush formulas also shown in claims); variables defined below; e.g. 2-[(aminocarbonyl)amino]-5-[[(3-chlorophenyl)acetyl]amino]thiophene-3-carboxamide (III)) are disclosed. IC50 values for inhibition of IKK-2 by >200 examples of I, etc. are tabulated. Although the methods of preparation are not claimed, example prepns. and/or characterization data for .apprx.300 examples of I, etc. are included. For example, III was prepared from (3-chlorophenyl)acetic acid and 2-[(aminocarbonyl)amino]-5-aminothiophene-3-carboxamide, which was prepared from the nitro analog, which was prepared by nitration of 2-[(aminocarbonyl)amino]thiophene-3-carboxamide. For I: Z = hydrido, halo, alkyl, cyano, and haloalkyl; R9 = alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, aralkyl, heteroaryl, and heteroaralkyl, or where R9 and R10 together with the atoms to which they are attached form a heterocyclic moiety. R9 is (un)substituted by ≥1 substituents independently amino, N-alkylamino, N,N-dialkylamino, N-arylamino, N-alkyl-N-arylamino, N-hydroxyamino, N-alkyl-N-hydroxyamino, N-aryl-N-hydroxyamino, halo, cyano, keto, hydroxy, alkyl, haloalkyl, cycloalkyl, alkoxy, alkenyl, alkenyloxy, aryl, aryloxy, aralkyl, aralkylcarbonyl, aralkylcarbonylamino, heteroarylcarbonyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, alkoxycarbonyl, aryloxycarbonyl, carboxy, alkoxyalkoxycarbonyl, alkoxycarbonylamino, heterocycloalkyl, heterocycloalkylalkyl, thiol, oxidosulfanyl, sulfino, alkylthio, alkylsulfinyl, alkylsulfonyl, cycloalkylthio, cycloalkylsulfinyl, cycloalkylsulfonyl, arylthio, acylsulfinyl, arylsulfonyl, heterocycloalkylthio, heterocycloalkylsulfinyl, heterocycloalkylsulfonyl, heteroarylthio, heteroarylsulfinyl, and heteroarylsulfonyl. R10 = hydrido, hydroxy, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl, or R10 and R9 together with the atoms to which they are attached form a heterocyclic moiety; R11 and R12 = hydrido, hydroxy, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl.

ACCESSION NUMBER: 2005:1193537 HCAPLUS
DOCUMENT NUMBER: 143:460021
TITLE: Preparation of substituted thiophene amide compounds as IKK-2 inhibitors for the treatment of inflammation and cancer
INVENTOR(S): Bonafoux, Dominique; Clare, Michael; Fletcher, Theresa Reher; Hamper, Bruce Cameron; Lennon, Patrick James; McGhee, William D.; Oburn, David Scott; Reding, Matthew Todd; Tollefson, Michael Brent; Wolfson, Serge G.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company LLC, USA
SOURCE: PCT Int. Appl., 165 pp.

L10 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105777	A1	20051110	WO 2005-IB1123	20050421

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2005-IB1123 20050421
OTHER SOURCE(S): MARPAT 143:460021
IT 869093-00-5P, 5-[(Aminocarbonyl)amino]-N-((1R,2R)-2-phenylcyclopropyl)thiophene-2,4-dicarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted thiophene amide compds. as IKK-2 inhibitors for treatment of inflammation and cancer)
RN 869093-00-5 HCAPLUS
CN 2,4-Thiophenedicarboxamide, 5-[(aminocarbonyl)amino]-N2-[(1R,2R)-2-phenylcyclopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 28 Oct 2005
GI



AB Novel imidazoles (I, variables are defined below) are provided that are useful as HMGCo-A reductase inhibitors to inhibit cholesterol biosynthesis. Accordingly, the compds. find utility as therapeutic agents to treat hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis. Also provided are pharmaceutical compns. of the compds. Methods of making and methods of using the compds. are also provided. For I, R2 and R5 = independently H, halogen, (un)substituted C1-C6 alkyl, C3-C8 cycloalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; R4 = halogen, H, (un)substituted C1-C6 alkyl, C3-C8 cycloalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, -(CH)nC(O)NR6R7; R8S(O)n-; -(CH2)nNR6R7, -(CH)nCOOR' or -(CH2)nCOR'; R6 and R7 = independently H, (un)substituted C1-C10 alkyl, C3-C8 cycloalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, -(CH)nCOR', -(CH)nCOOR', -(CH)nCONR'R" or -(CH2)nSOR'; or N, R6 and R7 taken together form a (un)substituted 4-11 member ring optionally containing ≤ two heteroatoms selected from O, N and S; R8 = (un)substituted aryl, aralkyl, alkyl, heteroaryl, or heteroaralkyl; R' and R" = independently H, (un)substituted C1-C12, alkyl, aryl or aralkyl; and n is 0-2. I may be in the form of a pharmaceutically acceptable salt, ester, amide, stereoisomer or lactone. For example, 2-[[2-[(4R,6R)-6-tert-Butoxycarbonylmethyl-2,2-dimethyl-[1,3]dioxan-4-yl]ethyl](4-fluorobenzoyl)amino]-3-methylbutyric acid is prepared in 5 steps from 3-Methyl-2-oxobutyric acid benzyl ester via 3-Methyl-2-trifluoromethanesulfonyloxybutyric acid benzyl ester, 2-[2-[(4R,6R)-6-tert-Butoxycarbonylmethyl-2,2-dimethyl-[1,3]dioxan-4-yl]ethylamino]-3-methylbutyric acid benzyl ester, and the benzyl ester of the product. No biol. test data is given.

ACCESSION NUMBER: 2005:1155542 HCAPLUS
DOCUMENT NUMBER: 143:405911
TITLE: Preparation of novel imidazoles as HMGCo-A reductase inhibitors for use in treating hyperlipidemia and other diseases
INVENTOR(S): Bolton, Gary Louis; Bowles, Daniel Merritt; Boyles, David Christopher
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 90 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

L10 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239857	A1	20051027	US 2005-105288	20050413
WO 2005105079	A2	20051110	WO 2005-US12255	20050412

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-563124P P 20040416
US 2004-600705P P 20040811
OTHER SOURCE(S): MARPAT 143:405911
IT 867305-24-6P, (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-4-(((1S,2R)-2-phenylcyclopropyl)carbamoyl)imidazol-1-yl]-3,5-dihydroxyheptanoic acid sodium salt
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of novel imidazoles as HMGCo-A reductase inhibitors for use in treating hyperlipidemia and other diseases)
RN 867305-24-6 HCAPLUS
CN 1H-Imidazole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-4-[[[(1S,2R)-2-phenylcyclopropyl]amino]carbonyl]-, monosodium salt, (βR,δR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L10 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 16 Sep 2005
AB The present invention relates to a novel method of treating and/or preventing psychiatric disorders in a subject by administering to the subject at last one Cox-2 inhibitor alone or in combination with one or more antidepressant agents. Compns., pharmaceutical compns. and kits are also described. Thus, celecoxib was prepared starting from 4'-methylacetophenone and ethyltrifluoroacetate followed by reaction with 4-sulfonamidophenylhydrazine. A composition is obtained by mixing sertraline and celecoxib.
ACCESSION NUMBER: 2005:1004550 HCAPLUS
DOCUMENT NUMBER: 143:311967
TITLE: Compositions for treating psychiatric disorders with COX-2 inhibitors alone and in combination with antidepressant agents
INVENTOR(S): Stephenson, Diane; Taylor, Duncan P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005084654	A2	20050915	WO 2005-US6818	20050302

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-549281P P 20040302
IT 2829-19-8, Rolicyprine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treating psychiatric disorders with COX-2 inhibitors alone and in combination with antidepressant agents)
RN 2829-19-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 25 Mar 2005
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Y = CH, CF, N; R1 = H, alkyl; R2 = CN, NO2, OH, (un)substituted alk(en/yn)yl, ; G1 = Ph, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms; each R5 = independently H, halo, CN, alkoxy, NO2, etc.; n = 1-3; R4 = H, (un)substituted alkyl; L = a bond, O, NH, N-alkyl, (un)substituted alkyl; G2 = (un)substituted monocyclyl, bicyclyl; and their optical isomers, racemates, tautomers, and pharmaceutically acceptable salts] were prepared as human neutrophil elastase (HNE) inhibitors for treating inflammation. Thus, acylation of 4-methylsulfonylbenzylamine•HCl with 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid (preparation given), iodination, and cyanation of the iodide with CuCN gave pyridone II. Selected I gave IC50 values for inhibition of HNE activity of less than 30 μM.
ACCESSION NUMBER: 2005:260029 HCAPLUS
DOCUMENT NUMBER: 142:316706
TITLE: Preparation of 2-pyridone derivatives as neutrophil elastase inhibitors and their use for treating inflammation
INVENTOR(S): Hansen, Peter; Lawitz, Karolina; Loenn, Hans; Nikitidis, Antonios
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026124	A1	20050324	WO 2004-SE1336	20040915

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: SE 2003-2487 A 20030918
OTHER SOURCE(S): MARPAT 142:316706
IT 848183-94-8P, N5,N5,6-Trimethyl-2-oxo-N3-((2R)-2-phenylcyclopropyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3,5-dicarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L10 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(drug candidate; prepn. of 2-pyridones as human neutrophil elastase inhibitors and their use for treating inflammation)
RN 848183-94-8 HCAPLUS
CN 3,5-Pyridinedicarboxamide, 1,2-dihydro-N5,N5,6-trimethyl-2-oxo-N3-[(2R)-2-phenylcyclopropyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 25 Mar 2005
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Y = CH, CF, N; R1 = H, alkyl; R2 = (un)substituted Ph, 5- or 6-membered heteroacyl containing 1 to 4 heteroatoms; G1 = Ph, 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms; each R5 = independently H, halo, CN, alkoxy, NO2, etc.; n = 1-3; R4 = H, (un)substituted alkyl; L = a bond, O, SO, SO2, S, NH, etc.; G2 = (un)substituted monocyclyl, bicyclyl; and their optical isomers, racemates, tautomers, and pharmaceutically acceptable salts] were prepared as human neutrophil elastase (HNE) inhibitors for treating inflammation. Thus, acylation of 4-methylsulfonylbenzylamine•HCl with 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid (preparation given), iodination, and Pd-cross coupling of the iodide with phenylboronic acid gave pyridone II. Selected I gave IC50 values for inhibition of HNE activity of less than 30 μM.
ACCESSION NUMBER: 2005:260028 HCAPLUS
DOCUMENT NUMBER: 142:316705
TITLE: Preparation of 2-pyridone derivatives as neutrophil elastase inhibitors and their use for treating inflammation
INVENTOR(S): Andersson, Marjana; Hansen, Peter; Loenn, Hans; Nikitidis, Antonios; Sjoelin, Petter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026123	A1	20050324	WO 2004-SE1335	20040915

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IO, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: SE 2003-2486 A 20030918
OTHER SOURCE(S): MARPAT 142:316705
IT 848140-80-7P, 6-Methyl-2-oxo-5-phenyl-N-((2R)-2-phenylcyclopropyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 2-pyridones as human neutrophil elastase inhibitors and their use for treating inflammation)
RN 848140-80-7 HCAPLUS
CN 3-Pyridinecarboxamide, 1,2-dihydro-6-methyl-2-oxo-5-phenyl-N-[(2R)-2-phenylcyclopropyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

WO 2004043924	A1	20040527	WO 2003-SE1739		20031111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2504766	AA	20040527	CA 2003-2504766		20031111
EP 1562902	A1	20050817	EP 2003-811170		20031111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016081	A	20050927	BR 2003-16081		20031111
US 2006035938	A1	20060216	US 2005-534720		20050512
NO 2005002818	A	20050711	NO 2005-2818		20050610
PRIORITY APPLN. INFO.:			SE 2002-3348	A	20021112
			SE 2003-388	A	20030212
			SE 2003-2120	A	20030722
			WO 2003-SE1739	W	20031111

OTHER SOURCE(S): MARPAT 141:7027

IT 694478-71-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-pyridone derivs. as inhibitors of neutrophile elastase)

RN 694478-71-2 HCAPLUS

CN 3-Pyridinecarboxamide, 1,2-dihydro-6-methyl-2-oxo-N-[(2S)-2-phenylcyclopropyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 27 May 2004

GI



I



II

AB Title compds. I [X = O, S; Y1 = N, CR2 and when R1 = OH, Y1 may also, in the tautomeric form, represent NR6; Y2 = CR3 and when Y1 = CR2, then Y2 may also represent N; R1 = H, alkyl; R2 = H, halo, alkyl; R3 = H, F; G1 = Ph, 5-6 membered heterocycle, etc.; R5 = H, halo, alkyl, etc.; n = 1-3; R4, R6 = H, alkyl, etc.; L = O, amino, alkyl, etc.; G2 = Ph, phenoxy, etc.] are prepared For instance, Et 3-[(4-chlorophenyl)amino]-3-oxopropanoate is reacted with 4-methoxy-3-buten-2-one (EtOH, NaOMe, reflux, 5 h) to give Et 1-(4-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate. This intermediate is saponified and coupled to 4-chlorobenzylamine (NMP, HBTu, HOBt, DIEA) to give II. Selected compds. have IC50 < 30 μM for human neutrophil elastase. I are useful in the treatment of inflammatory disorders.

ACCESSION NUMBER:	2004:428910 HCAPLUS
DOCUMENT NUMBER:	141:7027
TITLE:	Preparation of 2-pyridone derivatives as inhibitors of neutrophile elastase
INVENTOR(S):	Bladh, Hakan; Klingstedt, Tomas; Larsson, Joakim; Lawitz, Karolina; Lepistoe, Matti; Loenn, Hans; Nikitidis, Grigorios
PATENT ASSIGNEE(S):	Astrazeneca AB, Swed.
SOURCE:	PCT Int. Appl., 187 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 13 Feb 2004

GI



I

AB The present invention relates to acylated arylcycloalkylamines of the formula (I) including N-(trans-2-phenylcyclopropyl)carboxamides [wherein R1, R2 = each (un)substituted Ph, 1- or 2-naphthyl, or 5- to 10-membered, aromatic, monocyclic or bicyclic heterocycle containing one or more heteroatoms selected from the group consisting of N, O and S; n = an integer of 1-4]. These compds. upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. They are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. The diseases also include for the treatment of stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, peripheral artery occlusive disease, endothelial dysfunction, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance or a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or of women taking contraceptives. For example, N-(trans-2-phenylcyclopropyl)-3-amino-5-methylpyrazine-2-carboxamide and N-(trans-2-phenylcyclopropyl)-2,5-dimethyl-1-(thiophen-2-ylmethyl)-1H-pyrrole-3-carboxamide inhibited the activation of transcription of human endothelial nitric oxide synthetase in primary human umbilical vein code cells (HUVEC) with EC50 of 0.060 and <0.01 μM, resp.

ACCESSION NUMBER:	2004:117248 HCAPLUS
DOCUMENT NUMBER:	140:181465
TITLE:	Preparation of acylated arylcycloalkylamines and their use as pharmaceuticals for treatment of cardiovascular disorders
INVENTOR(S):	Strobel, Hartmut; Wohlfart, Paulus; Below, Peter
PATENT ASSIGNEE(S):	Aventis Pharma Deutschland GmbH, Germany
SOURCE:	Eur. Pat. Appl., 26 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1388535	A1	20040211	EP 2002-17587	20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2494628	AA	20040219	CA 2003-2494628	20030724
WO 2004014842	A1	20040219	WO 2003-EP8104	20030724
WO 2004014842	C1	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003250159	A1	20040225	AU 2003-250159		20030724
EP 1529031	A1	20050511	EP 2003-784056		20030724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013271	A	20050621	BR 2003-13271		20030724
JP 2005534706	T2	20051117	JP 2004-526766		20030724
US 2004082628	A1	20040429	US 2003-636001		20030807
NO 2005001110	A	20050301	NO 2005-1110		20050301
PRIORITY APPLN. INFO.:			EP 2002-17587	A	20020807
			US 2002-432312P	P	20021210
			WO 2003-EP8104	W	20030724

OTHER SOURCE(S): MARPAT 140:181465

IT 658683-57-9P 658683-59-1P 658683-60-4P
658683-61-5P 658683-63-7P 658683-64-8P
658683-67-1P 658683-71-7P 658683-72-8P
658683-80-8P 658683-82-0P 658683-83-1P
658683-84-2P 658683-85-3P 658683-86-4P
658683-87-5P 658683-88-6P 658683-89-7P
658683-91-1P 658683-92-2P 658684-01-6P
658684-08-3P 658684-10-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylated acylcycloalkylamines as regulators of transcription of endothelial nitric oxide synthase gene and pharmaceuticals for treatment of cardiovascular disorders)

RN 658683-57-9 HCAPLUS

CN 5-Oxazolecarboxamide, 2,4-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-59-1 HCAPLUS

CN Pyrazinecarboxamide, 3-amino-5-methyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 658683-58-0
CMF C15 H16 N4 O

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 658683-60-4 HCAPLUS

CN 5-Thiazolecarboxamide, 2-cyclopropyl-4-methyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-61-5 HCAPLUS

CN 3-Pyridinecarboxamide, 2,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-63-7 HCAPLUS

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Pyrazinecarboxamide, 3-amino-5,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 658683-62-6
CMF C16 H18 N4 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 658683-64-8 HCAPLUS

CN Pyrazinecarboxamide, 6-(methylamino)-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-67-1 HCAPLUS

CN 3-Pyridinecarboxamide, 6-(4-morpholinyl)-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 658683-71-7 HCAPLUS

CN 3-Pyridinecarboxamide, 6-methoxy-N-[(1R,2S)-2-phenylcyclopropyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 658683-70-6
CMF C16 H16 N2 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 658683-72-8 HCAPLUS

CN 5-Thiazolecarboxamide, 2-methyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-80-8 HCAPLUS

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 2,5-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-1-(2-thienylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-82-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-4-[(1-methylethyl)sulfonyl]-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-83-1 HCAPLUS
CN 1H-Pyrazole-4-carboxamide, 5-methyl-1-phenyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-84-2 HCAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-phenyl-N-[(1R,2S)-2-phenylcyclopropyl]-5-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 658683-85-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2,5-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-1-(4-pyridinylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-86-4 HCAPLUS
CN 5-Thiazolecarboxamide, 2,4-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-87-5 HCAPLUS
CN 3-Pyridinecarboxamide, 2-amino-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 658683-88-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-methyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-89-7 HCAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-6-methyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-91-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-(methoxymethyl)-N-[(1R,2S)-2-phenylcyclopropyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 658683-90-0
CMF C17 H18 N2 O2

Relative stereochemistry.



CM 2

CRN 76-05-1

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C2 H F3 O2

RN 658683-92-2 HCAPLUS
CN Pyrazinecarboxamide, 3-amino-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658684-01-6 HCAPLUS
CN 3-Pyridinecarboxamide, 2-amino-4,6-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 658684-00-5
CMF C17 H19 N3 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 658684-08-3 HCAPLUS
CN 2-Thiophenecarboxamide, 5-methyl-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Relative stereochemistry.



RN 658684-10-7 HCAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Pyrazole-4-carboxamide, 1-(4-fluorophenyl)-N-(2-phenylcyclopropyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 09 May 2003
GI



I

AB Pyrazolecarboxamides and -sulfonamides were prepared for use in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels, especially pain and chronic pain. Thus, the amide I was prepared by amidation of the acid chloride with the amine and showed activity at the PN3 Na channel in the 4.1-10 μM range.

ACCESSION NUMBER: 2003:356201 HCAPLUS
DOCUMENT NUMBER: 138:368888
TITLE: Pyrazolecarboxamides and -sulfonamides as sodium channel blockers
INVENTOR(S): Atkinson, Robert Nelson; Gross, Michael Francis
PATENT ASSIGNEE(S): Icagen, Inc., USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037274	A2	20030508	WO 2002-US35172	20021101
WO 2003037274	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465207	AA	20030508	CA 2002-2465207	20021101
EP 1451160	A2	20040901	EP 2002-799175	20021101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005049237	A1	20050303	US 2002-286304	20021101
PRIORITY APPLN. INFO.:			US 2001-335958P	P 20011101
			WO 2002-US35172	W 20021101

OTHER SOURCE(S): MARPAT 138:368888
IT 521924-29-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolecarboxamides and -sulfonamides as sodium channel blockers)
RN 521924-29-8 HCAPLUS

L10 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 May 2003
GI



I

AB The title 4,5-dihydroxypyrimidine-6-carboxamides [I; R1 = H, alkyl, haloalkyl, alkoxy, etc.; R2 = H, alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = H, alkyl; R4 = H, alkyl, haloalkyl, etc.] which are inhibitors of HIV integrase and inhibitors of HIV replication, and therefore are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS, were prepared Thus, refluxing N-hydroxythiophene-2-carboximidamide with di-Me acetylenedicarboxylate in CHCl3 followed by reacting the resulting Me 5,6-dihydroxy-2-(2-thienyl)pyrimidine-4-carboxylate with 4-fluorobenzylamine in DMF afforded I [R1 = 2-thienyl; R2 = H; R3 = 4-FC6H4CH2; R4 = H]. The compds. I are employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. I and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

ACCESSION NUMBER: 2003:334911 HCAPLUS
DOCUMENT NUMBER: 138:354000
TITLE: Preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase
INVENTOR(S): Di Francesco, Maria Emilia; Gardelli, Cristina; Harper, Steven; Matassa, Victor Giulio; Muraglia, Ester; Nizi, Emanuela; Pace, Paola; Pacini, Barbara; Petrocchi, Alessia; Poma, Marco; Summa, Vincenzo
PATENT ASSIGNEE(S): Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Italy
SOURCE: PCT Int. Appl., 315 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035076	A1	20030501	WO 2002-GB4742	20021021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463975	AA	20030501	CA 2002-2463975	20021021
EP 1441734	A1	20040804	EP 2002-801949	20021021

L10 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP 2005510500	T2	20050421	JP 2003-537643	20021021
US 2005075356	A1	20050407	US 2004-493279	20040420
PRIORITY APPLN. INFO.:			US 2001-348195P	P 20011026
			WO 2002-GB4742	W 20021021

OTHER SOURCE(S): MARPAT 138:354000

IT **519022-98-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase)

RN 519022-98-1 HCAPLUS

CN 4-Pyrimidinecarboxamide, 1,6-dihydro-5-hydroxy-6-oxo-N-(2-phenylcyclopropyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 21 Jan 2003

AB The aim of the work was to discriminate between antibacterial and non-antibacterial drugs by topol. methods and to select new potential antibacterial agents from among new structures. The method used for antibacterial activity selection was a linear discriminant anal. (LDA). It is possible to obtain a QSAR interpretation of the information contained in the discriminant function. We make use of the pharmacol. distribution diagrams (PDDs) as a visualizing technique for the identification and selection of new antibacterial agents.

ACCESSION NUMBER:	2003:49279 HCAPLUS
DOCUMENT NUMBER:	139:159420
TITLE:	Discrimination and selection of new potential antibacterial compounds using simple topological descriptors
AUTHOR(S):	Murcia-Soler, Miguel; Perez-Gimenez, Facundo; Garcia-March, Francisco J.; Salabert-Salvador, M. Teresa; Diaz-Villanueva, Wladimiro; Medina-Casamayor, Piedad
CORPORATE SOURCE:	Faculty of Pharmacy, Department of Physical Chemistry, Universitat de Valencia, Valencia, Spain
SOURCE:	Journal of Molecular Graphics & Modelling (2003), 21(5), 375-390 CODEN: JMGMFI; ISSN: 1093-3263
PUBLISHER:	Elsevier Science Inc.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

IT **2829-19-8**, Rolicyprine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discrimination and selection of new potential antibacterial compds. using simple topol. descriptors)

RN 2829-19-8 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 22 Sep 2000

GI



I



II

AB Title compds. [I; A = heteromonocyclic ring containing 5-6 member; fused heteropolycyclic ring containing 8-14 member; X1 = C, CH; X2 = bond, NHCH2CO, NHCH2CH2SO2, alkylamino; R1 = alkylaminocarbonyl, alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl; R2 = H, alkyl; R3 = alkyl; R4 = H, alkyl; R3R4 = cycloalkylene, heterocycloalkylene; R5 = H; R6 = H; R5R6 = oxo; R7 = CN, Cl, Br, F, NO2, H; R8 = alkyl, alkylidene, CN, Cl, F, Br, NO2; n = 0, 1, 2, 3], N-oxide derivs., prodrug derivs., protected derivs., individual isomers, mixts. of isomers, and pharmaceutically acceptable salts and compns. with bisphosphonic acids or acid esters as excipients are prepared as cathepsin K and cathepsin S inhibitors. Title compds. are administering to animal in treating diseases which cysteine protease activity contributes to the pathol. and/or symptomatol. The diseases are autoimmune disorder, allergic disorder, allogeneic immune response, excessive elastolysis, cardiovascular disorders, fibril formation, etc. Thus, the title compound II was prepared

ACCESSION NUMBER:	2000:666718 HCAPLUS
DOCUMENT NUMBER:	133:252041
TITLE:	Preparation of amine derivatives as cathepsin K and cathepsin S inhibitors and in treating pathology and/or symptomatology of diseases caused by cysteine protease activity
INVENTOR(S):	Link, John O.; Martelli, Arnold J.; Martichonok, Valeri; Patterson, John W.; Saunders, Oliver L.; Zipfel, Sheila
PATENT ASSIGNEE(S):	Axys Pharmaceuticals, Inc., USA
SOURCE:	PCT Int. Appl., 223 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055144	A1	20000921	WO 2000-US6885	20000315

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,

L10 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY; DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2367352	AA	20000921	CA 2000-2367352	20000315
AU 2000037507	A5	20001004	AU 2000-37507	20000315
AU 774664	B2	20040701		
EP 1161422	A1	20011212	EP 2000-916397	20000315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009044	A	20020115	BR 2000-9044	20000315
TR 200103335	T2	20020422	TR 2001-200103335	20000315
JP 2002539201	T2	20021119	JP 2000-605574	20000315
EE 200100486	A	20030217	EE 2001-486	20000315
US 6576630	B1	20030610	US 2000-525507	20000315
EP 1516877	A1	20050323	EP 2004-15656	20000315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ZA 2001007496	A	20021211	ZA 2001-7496	20010911
NO 2001004483	A	20011101	NO 2001-4483	20010914
BG 105969	A	20020531	BG 2001-105969	20011002
HR 2001000736	A1	20021231	HR 2001-736	20011012
US 2003232864	A1	20031218	US 2003-354888	20030128
AU 2004201071	A1	20040408	AU 2004-201071	20040315

PRIORITY APPLN. INFO.:	US 1999-124421P	P	19990315
	AU 2000-37507	A3	20000315
	EP 2000-916397	A3	20000315
	US 2000-525507	A1	20000315
	WO 2000-US6885	W	20000315

OTHER SOURCE(S): MARPAT 133:252041

IT **294884-90-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amine derivs. as cathepsin K and cathepsin S inhibitors useful in disorders caused by cysteine protease activity)

RN 294884-90-5 HCAPLUS

CN Carbamic acid, [(1S)-3-methyl-1-[[[(1S)-3-phenyl-1-[[4-[[[(1S,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]carbonyl]propyl]amino]carbonyl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 May 2000
GI



AB Described are novel compds. of general formula [I: wherein A is a bond or optionally substituted alkylene; R1 is one or more groups which may be the same or different from each other and are selected from among hydrogen, alkoxy and haloalkoxy; R2 is hydrogen, (substituted) benzyl, (substituted) alkyl or (substituted) alkanoyl; and R3 is hydrogen, (substituted) cycloalkyl, (substituted) cycloalkenyl, (substituted) aryl, or a (substituted) heterocyclic group, with the proviso that the cases wherein R1 is hydrogen, A is a free valency or methylene, and R3 is Ph or cyclohexyl or those wherein A is alkylene and R3 is hydrogen are excepted.], pest controllers such as plant fungicides, insecticides, and herbicides containing the same; and a process for the preparation of the compds. Thus, a solution of 1.85 g 4-phenoxyaniline in 25 mL DMF was added dropwise to a suspension of 1.39 g 3-hydroxypicolinic acid, 1.95 g carbonyl diimidazole, and 30 mL DMF and stirred overnight to give 41% 3-hydroxy-4'-phenoxypicolinanilide (II). II at 100 ppm protected 80-100% rice seedlings against Pyricularia oryzae.

ACCESSION NUMBER: 2000:314676 HCAPLUS
DOCUMENT NUMBER: 132:334362
TITLE: Preparation of picolinamide derivatives and pest controllers containing the same as the active ingredient
INVENTOR(S): Imamura, Keiichi; Mitomo, Kouichi; Yamada, Natsuko; Yamamoto, Kazumi; Teraoka, Takeshi; Sakanaka, Osamu; Kurihara, Hiroshi; Taniguchi, Makoto
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000026191	A1	20000511	WO 1999-JP6142	19991104
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2353627	AA	20000511	CA 1999-2353627	19991104
EP 1134214	A1	20010919	EP 1999-954375	19991104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 771975	B2	20040408	AU 2000-10768	19991104
PRIORITY APPLN. INFO.:			JP 1998-313688 A	19981104
			WO 1999-JP6142 W	19991104

OTHER SOURCE(S): MARPAT 132:334362
IT 267416-05-7P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of picolinamide derivs. as pest controllers)
RN 267416-05-7 HCAPLUS
CN 2-Pyridinecarboxamide, 3-hydroxy-4-methoxy-N-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Jan 1999
GI



AB The title compds. I [n = 2-5; X = 1,2-C6H4, 1,3-C6H4, 1,4-C6H4; R = R1 = H, RR1 = double bond; R2 = alkyl, alkenyl, alkynyl, 2-phenylcyclopropyl, C-4 substituted Ph, C-4 substituted cyclohexyl, R3-substituted alkyl or oxaalkyl [R3 = (un)substituted cycloalkyl, Ph, tetrahydropyranyl, morpholino, piperidino, pyrrolidino, etc.]] and their salts, which possess thromboxane receptor antagonism activity, inhibited thromboxane synthase, inhibited induced blood platelet aggregation, and demonstrated an absence of TXA2 agonist activity, were prepared by Stille coupling reactions of pyridines II and alkenes III (Y, Z = Br, iodo, F3CSO3, trialkylstannyl; R4 = carboxy protecting group) in the presence of a Stille palladium coupling catalyst. Alternatively, I were prepared by Wittig olefination reactions of appropriate 3-pyridinyl oxazolylphenyl ketones.

ACCESSION NUMBER: 1999:3310 HCAPLUS
DOCUMENT NUMBER: 130:52408
TITLE: Processes for the preparation of α-(3-pyridinyl)-ω-[(carbamoyloxazolyl)phenyl] alkenoic acids with thromboxane receptor antagonism activity
INVENTOR(S): Nelson, Katrina Ann; Nunes, Joseph John
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: U.S., 32 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5849922	A	19981215	US 1997-862710	19970523
US 5990308	A	19991123	US 1998-151122	19980910
US 6031095	A	20000229	US 1998-150996	19980910
PRIORITY APPLN. INFO.:			US 1996-18749P P	19960531
			US 1997-862710 A3	19970523

OTHER SOURCE(S): CASREACT 130:52408; MARPAT 130:52408
IT 200399-88-8P 200399-89-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (pyridinyl)[(carbamoyloxazolyl)phenyl] alkenoic acids with thromboxane receptor antagonism and thromboxane synthase inhibiting activity)

L10 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 200399-88-8 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 200399-89-9 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



IT 200400-45-9P 200400-46-0P 200400-53-9P
200400-54-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyridinyl)[(carbamoyloxazolyl)phenyl] alkenoic acids with thromboxane receptor antagonism and thromboxane synthase inhibiting activity)
RN 200400-45-9 HCAPLUS
CN 4-Oxazolecarboxamide, 4,5-dihydro-N-[(1S,2R)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 200400-46-0 HCAPLUS
CN 4-Oxazolecarboxamide, 4,5-dihydro-N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200400-53-9 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 200400-54-0 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L10 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 01 Jan 1999
GI



AB Title compds. [I; R = alk(en)yl, phenylalkyl, heterocyclylalkyl, etc.; R1 = ZCR2:CH(CH2)nCO2H; R2 = 3-pyridyl throughout; Z = phenylene; n = 2-5; dashed line = optional bond] were prepared as thromboxane receptor and synthase antagonists. Thus, Me (E)-7-(4-carboxyphenyl)-7-(3-pyridyl)-6-heptenoate was amidated by N-(4-cyclohexylbutyl)-O-(tert-butyldimethylsilyl)-L-serinamide (preparation each given) and the deprotected product cyclized to give, after dehydrogenation and saponification, I [R = 4-cyclohexylbutyl, R1 = (E)-C6H4(CR2:CH(CH2)4CO2H)-4, dashed line = bond]. Data for biol. activity of I were given.

ACCESSION NUMBER: 1998:816109 HCAPLUS
DOCUMENT NUMBER: 130:66485
TITLE: Preparation of α-[(carbamoyl-2-oxazolyl)phenyl-α-(3-pyridyl)alkenoates as thromboxane A2 antagonists
INVENTOR(S): Jakubowski, Joseph Anothony; Mais, Dale Eugene; Takeuchi, Kumiko
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: U.S., 28 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 5849766	A	19981215	US 1997-862505		19970523
US 6075147	A	20000613	US 1998-148288		19980904
US 6114534	A	20000905	US 1998-148461		19980904
PRIORITY APPLN. INFO.:			US 1996-18595P	P	19960531
			US 1997-862505	A3	19970523

OTHER SOURCE(S): MARPAT 130:66485
IT 200399-88-8P 200399-89-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of α-[(carbamoyl-2-oxazolyl)phenyl-α-(3-pyridyl)alkenoates as thromboxane A2 antagonists)
RN 200399-88-8 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.

L10 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 200399-89-9 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



IT 200400-45-9P 200400-46-0P 200400-53-9P
200400-54-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of α-[(carbamoyl-2-oxazolyl)phenyl-α-(3-pyridyl)alkenoates as thromboxane A2 antagonists)
RN 200400-45-9 HCAPLUS
CN 4-Oxazolecarboxamide, 4,5-dihydro-N-[(1S,2R)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200400-46-0 HCAPLUS
CN 4-Oxazolecarboxamide, 4,5-dihydro-N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, (4S)- (9CI) (CA INDEX NAME)

L10 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 200400-53-9 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 200400-54-0 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
inhibitor activity of carbamoyloxazolylphenyl(pyridyl)heptenoic acids)

RN 200399-88-8 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 200399-89-9 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



IT 200400-53-9P 200400-54-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and thromboxane receptor antagonist and thromboxane synthase inhibitor activity of carbamoyloxazolylphenyl(pyridyl)heptenoic acids)

RN 200400-53-9 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

L10 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 03 Dec 1998
GI



AB A novel series of oxazolecarboxamide-substituted e-phenyl-e-(3-pyridyl)alkenoic acid derivs. was discovered as potent dual-acting agents to block the TXA2 receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacol. of this series of compds. are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compds. and to correlate the biol. activity with lipophilicity of the compds. The most potent in the series was (E)-7-[4-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid (I) with Kd = 9.9 ± 0.4 nM for thromboxane receptor antagonism and IC50 = 55.0 ± 17.9 nM for thromboxane synthase inhibition. I was a selective TRA/TSI which exhibited desirable characteristics for oral activity, shunt effect to elevate PGI2 level, and absence of agonist activity.

ACCESSION NUMBER: 1998:756609 HCAPLUS
DOCUMENT NUMBER: 130:110182
TITLE: Development of Dual-Acting Agents for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition. 3. Synthesis and Biological Activities of Oxazolecarboxamide-Substituted e-Phenyl-e-(3-pyridyl)alkenoic Acid Derivatives and Related Compounds
AUTHOR(S): Takeuchi, Kumiko; Kohn, Todd J.; True, Timothy A.; Mais, Dale E.; Wikel, James H.; Utterback, Barbara G.; Wyss, Virginia L.; Jakubowski, Joseph A.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA
SOURCE: Journal of Medicinal Chemistry (1998), 41(27), 5362-5374
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 200399-88-8P 200399-89-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and thromboxane receptor antagonist and thromboxane synthase

L10 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 200400-54-0 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 26 Feb 1998
GI



AB Title compds. [I; R = alk(en)yl, cycloalkylalkyl, phenylalkyl, etc.; R1 = ZCR2:CH(CH2)nCO2H; R2 = 3-pyridiyl; Z = phenylene; n = 2-5; dashed line = optional addnl. bond] were prepared Thus, 4-(Me3CMe2SiO)C6H4CHO was condensed with 3-bromopyridine and the oxidized product condensed with BrPh3P(CH2)5CO2H to give, in 2 addnl. steps, (E)-4-(HO2C)C6H4CR2:CH(CH2)4CO2Me (R2 = 3-pyridiyl) which was condensed with (S)-Me3CMe2SiOCH2CH(NH2)CONHR (R = 4-cyclohexylbutyl)(preparation given) to give, in 3 addnl. steps, I [R = 4-cyclohexylbutyl, R1 = (E)-C6H4[CR2:CH(CH2)4CO2H]-4, R2 = 3-pyridiyl, dashed line = addnl. bond]. Data for biol. activity of I were given.

ACCESSION NUMBER: 1998:116096 HCAPLUS
DOCUMENT NUMBER: 128:140692
TITLE: Preparation of ω-[(carbamoyloxazolyl)phenyl]alkenoic acids as thromboxane receptor and synthase inhibitors
INVENTOR(S): Nelson, Katrina Ann; Nunes, Joseph John
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 52 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 816361	A2	19980107	EP 1997-303656	19970529
EP 816361	A3	19980408		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CA 2206469	AA	19971130	CA 1997-2206469	19970528
JP 10059966	A2	19980303	JP 1997-141619	19970530
PRIORITY APPLN. INFO.:			US 1996-18749P P	19960531
			GB 1996-13219 A	19960625

OTHER SOURCE(S): MARPAT 128:140692
IT **200399-88-8P 200399-89-9P 201993-61-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ω-[(carbamoyloxazolyl)phenyl]alkenoic acids as thromboxane receptor and synthase inhibitors)
RN 200399-88-8 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.

L10 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 200399-89-9 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 201993-61-5 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[(2-phenylcyclopropyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, [1α(E),2β]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



L10 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT **200400-45-9P 200400-46-0P 200400-53-9P**
200400-54-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ω-[(carbamoyloxazolyl)phenyl]alkenoic acids as thromboxane receptor and synthase inhibitors)
RN 200400-45-9 HCAPLUS
CN 4-Oxazolecarboxamide, 4,5-dihydro-N-[(1S,2R)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200400-46-0 HCAPLUS
CN 4-Oxazolecarboxamide, 4,5-dihydro-N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200400-53-9 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 200400-54-0 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L10 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L10 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Dec 1997
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; n = 2-5; L = ortho-, meta- or para-phenylene; Ra = H; RaRa = a bond; R = C3-12 alkyl, C3-12 alkenyl, C3-12 alkynyl, etc.] in either the E-form, the Z-form or a mixture thereof, which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivs. bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the Ph ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, were prepared and formulated. Thus, reaction of the acid II with L-serinamide III in the presence of HOBT and DCC in THF followed by TBS-group removal, cyclization of the resulting hydroxybisamide IV in the presence of PPh3, iPr2NEt in CCl4/MeCN, and hydrolysis of the ester V afforded the acid (4S)-(E)-VI which showed IC50 of 82.1 nM against thromboxane synthase.

ACCESSION NUMBER: 1997:801923 HCAPLUS
DOCUMENT NUMBER: 128:61507
TITLE: Preparation of carbamoyl-substituted oxazoles as thromboxane receptor antagonists
INVENTOR(S): Jakubowski, Joseph Anthony; Mais, Dale Eugene; Takeuchi, Kumiko
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 811621	A2	19971210	EP 1997-303662		19970529
EP 811621	A3	19980204			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
CA 2206466	AA	19971130	CA 1997-2206466		19970528
JP 10059965	A2	19980303	JP 1997-141590		19970530
PRIORITY APPLN. INFO.:			US 1996-18595P	P	19960531
			GB 1996-13222	A	19960625

OTHER SOURCE(S): MARPAT 128:61507
IT **200399-88-8P 200399-89-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbamoyl-substituted oxazoles as thromboxane receptor antagonists)
RN 200399-88-8 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.

L10 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 200400-46-0 HCAPLUS
CN 4-Oxazolecarboxamide, 4,5-dihydro-N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200400-53-9 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 200400-54-0 HCAPLUS
CN 4-Oxazolecarboxamide, N-[(1R,2S)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



L10 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 200399-89-9 HCAPLUS
CN 6-Heptenoic acid, 7-[4-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridinyl)-, (6E)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



IT **200400-45-9P 200400-46-0P 200400-53-9P 200400-54-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carbamoyl-substituted oxazoles as thromboxane receptor antagonists)
RN 200400-45-9 HCAPLUS
CN 4-Oxazolecarboxamide, 4,5-dihydro-N-[(1S,2R)-2-phenylcyclopropyl]-2-[4-(3-pyridinylcarbonyl)phenyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 08 Aug 1997
GI



I

AB The title compds. I [R1 = H, alkyl; R2, R3 = H, alkyl; R4 = H, nitro, etc.; or R1R4= ring, R2R3 = ring; a proviso is given] are prepared I [R1 = R2 = R3 = R4 = H] at 5 mg/pot gave 98% control of Pyricularia oryzae.

ACCESSION NUMBER: 1997:500124 HCAPLUS
DOCUMENT NUMBER: 127:121638
TITLE: Preparation of isonicotinamide derivatives as agrochemical biocides
INVENTOR(S): Asada, Toru; Tsuboi, Hiroyuki; Yoshioka, Nobuyuki; Koiso, Teruhiro; Goto, Takashi
PATENT ASSIGNEE(S): Dainippon Ink and Chemicals, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09165374	A2	19970624	JP 1995-327050	19951215
PRIORITY APPLN. INFO.:			JP 1995-327050	19951215

OTHER SOURCE(S): MARPAT 127:121638
IT **192633-95-7P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isonicotinamide derivs. as agrochem. biocides)
RN 192633-95-7 HCAPLUS
CN 4-Pyridinecarboxamide, 2,6-dichloro-N-[2-(4-nitrophenyl)cyclopropyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 29 May 1993
GI



AB Triazolinones I (R1 = alkyl or cycloalkyl, R2 = aryl, aralkyl, arylalkenyl or arylalkynyl, X = O or S, Q = O or S) and precursors to I are prepared as herbicides. Treatment of 3.9 g of 4-(4-methylpent-2-ylideniimino)-3-methyl-1,2,4-triazolin-5-one in 100 mL MeCN containing 0.2 g DBU and 4.5 g 2-methyl-4-(2-chlorophenyl)-2-butyl isocyanate gave 97% of II. Many I were active both pre- and postemergent.

ACCESSION NUMBER: 1993:213082 HCAPLUS
DOCUMENT NUMBER: 118:213082
TITLE: preparation of triazolinone derivatives as herbicides
INVENTOR(S): Kuhnt, Dietmar; Mueller, Klaus Helmut; Findeisen, Kurt; Koenig, Klaus; Luerssen, Klaus; Santel, Hans Joachim; Schmidt, Robert R.
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 511569	A1	19921104	EP 1992-106779	19920421
R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL				
DE 4114074	A1	19921105	DE 1991-4114074	19910430
US 5273958	A	19931228	US 1992-871788	19920420
JP 05194434	A2	19930803	JP 1992-134490	19920428

PRIORITY APPLN. INFO.: DE 1991-4114074 A 19910430
OTHER SOURCE(S): CASREACT 118:213082; MARPAT 118:213082
IT 146850-59-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 146850-59-1 HCAPLUS
CN 1H-1,2,4-Triazole-1-carboxamide, 4-amino-4,5-dihydro-3-methyl-5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L10 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 28 Jun 1991
GI

AB Several brain-targeting chemical delivery systems (CDS) based on a dihydropyridine ⇔ pyridinium salt type redox system were synthesized for the monoamine oxidase inhibitor tranylcypromine (I). The dihydronicotinate moiety was chemical attached to the amino group of I be either an amide or substituted carbamate linkages. Physicochem. studies of the new derivs., including chromatog. Rm detns., were performed. Only the substituted carbamate-type derivs. manifested an increased lipophilicity relative to the parent compound In vitro oxidation stability studies were also performed on selected derivs. using a ferricyanide-mediated method. Results of this assay showed that the dihydropyridine-type derivs. oxidized to the resp. quaternary salt forms with stabilities which empirically correlated with other effective CDSs. Preliminary in vivo studies performed in rats indicated that some of the new derivs. exerted significant biolog. activity.

ACCESSION NUMBER: 1991:240548 HCAPLUS
DOCUMENT NUMBER: 114:240548
TITLE: Redox derivatives of tranylcypromine: syntheses, properties, and monoamine oxidase inhibitor activity of some chemical delivery systems
AUTHOR(S): Prokai-Tatrai, Katalin; Pop, Emil; Anderson, Wesley; Lin, Jun Liang; Brewster, Marcus E.; Bodor, Nicholas
CORPORATE SOURCE: Coll. Pharm., Univ. Florida, Gainesville, FL, 32610, USA
SOURCE: Journal of Pharmaceutical Sciences (1991), 80(3), 255-61
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:240548
IT 133941-05-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)
RN 133941-05-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 133950-61-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and properties and monoamine oxidase inhibitory activity of)
RN 133950-61-5 HCAPLUS
CN 3-Pyridinecarboxamide, 1,4-dihydro-1-methyl-N-(2-phenylcyclopropyl)-,

L10 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 133941-06-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 133941-06-7 HCAPLUS
CN Pyridinium, 1-methyl-3-[[(2-phenylcyclopropyl)amino]carbonyl]-, iodide, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● I⁻

L10 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 09 Dec 1989
GI



I

AB A symposium on the prepn and activity of the title compds. (2S,3R)- and 2R,3S)-I (X = Gly, Pro) toward substance P receptors.
ACCESSION NUMBER: 1989:614919 HCAPLUS
DOCUMENT NUMBER: 111:214919
TITLE: Synthesis and biological activities of structurally constrained cyclopropylphenylalanine-containing analog of septide, a highly selective peptide for substance P receptor subtype
AUTHOR(S): Yoshitomi, Haruko; Shimohigashi, Yasuyuki; Matsumoto, Hiroshi; Waki, Michinori; Takano, Yukio; Kamiya, Hiroo; Stammer, Charles
CORPORATE SOURCE: Fac. Sci., Kyushu Univ., Fukuoka, 812, Japan
SOURCE: Peptide Chemistry (1989), Volume Date 1988, 26th, 43-6
CODEN: PECHDP; ISSN: 0388-3698
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **123450-26-0P 123450-27-1P 123536-56-1P 123536-57-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and binding of, to substance P receptors)
RN 123450-26-0 HCAPLUS
CN L-Methioninamide, 5-oxo-L-prolyl-(1S-trans)-2-phenyl-1-aminocyclopropanecarbonyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— SMe

L10 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L10 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 123450-27-1 HCAPLUS
CN L-Methioninamide, 5-oxo-L-prolyl-(1R-trans)-2-phenyl-1-aminocyclopropanecarbonyl-L-phenylalanyl-L-prolyl-L-leucyl- (9CI) (CA INDEX NAME)



RN 123536-56-1 HCAPLUS
CN L-Methioninamide, 5-oxo-L-prolyl-(1R-trans)-2-phenyl-1-aminocyclopropanecarbonyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— SMe

RN 123536-57-2 HCAPLUS
CN L-Methioninamide, 5-oxo-L-prolyl-(1S-trans)-2-phenyl-1-aminocyclopropanecarbonyl-L-phenylalanyl-L-prolyl-L-leucyl- (9CI) (CA INDEX NAME)

L10 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Feb 1989
AB The 13C NMR spectra of a series of novel 2(5H)-furanones were studied. The assignments of the carbon resonances were made on the basis of chemical shifts, long-range carbon-hydrogen couplings, internal comparison and known reference sources.
ACCESSION NUMBER: 1989:38510 HCAPLUS
DOCUMENT NUMBER: 110:38510
TITLE: Carbon-13 NMR spectra of some novel 2(5H)-furanone and 3(2H)-furanone derivatives
AUTHOR(S): Kuipers, William J.; Mack, Robert A.; Georgiev, Vassil S.
CORPORATE SOURCE: Pharm. Div., Pennwalt Corp., Rochester, NY, 14623, USA
SOURCE: Magnetic Resonance in Chemistry (1988), 26(1), 89-91
CODEN: MRCHEG; ISSN: 0749-1581
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **106212-49-1 106212-50-4 106212-51-5 106212-53-7**
RL: PRP (Properties)
(carbon-13 NMR of)
RN 106212-49-1 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-4-[(3-methylphenyl)amino]-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-50-4 HCAPLUS
CN 3-Furancarboxamide, 4-[(4-chlorophenyl)amino]-2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-51-5 HCAPLUS
CN 3-Furancarboxamide, 4-[(3,5-dimethoxyphenyl)amino]-2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 106212-53-7 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-4-[(3-nitrophenyl)amino]-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 106212-53-7 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-4-[(3-nitrophenyl)amino]-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Dec 1988
GI



AB A novel rearrangement of furancarboxamides I (R = aryl, trans-2-phenylcyclopropyl; R1 = H, Me, R2 = aryl; NR1R2 = NEt2, morpholino, piperidino, pyrrolidino, 1,2,3,4-tetrahydro-1-quinolinyl) in refluxing aqueous EtOH cont. KOH gave 22-100% furancarboxylic acids II.

ACCESSION NUMBER: 1988:630669 HCAPLUS
DOCUMENT NUMBER: 109:230669
TITLE: A novel rearrangement of 2(5H)-furanones
AUTHOR(S): Mack, Robert A.; DeCory, Thomas R.; Georgiev, Vassil St.
CORPORATE SOURCE: Dep. Org. Chem., Penwalt Corp., Rochester, NY, 14623, USA
SOURCE: Helvetica Chimica Acta (1988), 71(4), 783-7
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 109:230669
IT **106212-50-4 106212-52-6 106212-53-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(rearrangement of, aminooxofurancarboxylic acid from base-promoted)
RN 106212-50-4 HCAPLUS
CN 3-Furancarboxamide, 4-[(4-chlorophenyl)amino]-2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-52-6 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-4-[[3-(trifluoromethyl)phenyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 11 Jun 1988
GI



AB The synthesis and antiallergic activity of (arylamino)dihydrooxo-N-cyclopropyl)furancarboxamides I (R = 3-Me, 3-NO2, 3-CF3, 4-Cl) and II were described. Treatment of N-substituted aminodihydrooxofurancarboxylic acids III with chlorooxobis(2-oxo-1,3-oxazolidin-3-yl)phosphorus and amines IV (R = 3-Me, 3-NO2, 3-CF3, 4-Cl) and V in the presence of Et3N gave I, via rearrangement. Antiallergic activities of I and II were tested in the dermal vascular permeability and active anaphylaxis assays in rats. I (R = 4-Cl) inhibited serotonin, histamine, and bradykinin by 94, 92, and 100% resp., when administered i.p. to rats at doses of 100 mg/kg.

ACCESSION NUMBER: 1988:204431 HCAPLUS
DOCUMENT NUMBER: 108:204431
TITLE: Drug-induced modifications of the immune response. Part 9. 4-(Arylamino)-2,5-dihydro-2-oxo-N-(trans-2-phenylcyclopropyl)furan-3-carboxamides as novel antiallergic compounds
AUTHOR(S): Georgiev, Vassil St.; Mack, Robert A.; Walter, David J.; Radov, Lesley A.; Baer, Jane E.
CORPORATE SOURCE: Pharm. Div., Penwalt Corp., Rochester, NY, 14623, USA
SOURCE: Helvetica Chimica Acta (1987), 70(6), 1526-30
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:204431
IT **106212-49-1P 106212-50-4P 106212-51-5P 106212-52-6P 106212-53-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiallergic activity of)
RN 106212-49-1 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-4-[(3-methylphenyl)amino]-2-oxo-N-(2-

L10 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-50-4 HCAPLUS
CN 3-Furancarboxamide, 4-[(4-chlorophenyl)amino]-2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-51-5 HCAPLUS
CN 3-Furancarboxamide, 4-[(3,5-dimethoxyphenyl)amino]-2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-52-6 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-4-[[3-(trifluoromethyl)phenyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 106212-53-7 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-4-[(3-nitrophenyl)amino]-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 29 May 1987
GI



AB The title compds. [I; R = (substituted) Ph; R1 = H, alkyl; R2 = (substituted) Ph, trans-phenylcyclopropyl] were prepared as allergy inhibitors. Thus, 4-ClC6H4NH2 reacted with aminofuranonecarboxylate II in the presence of Et3N and bis(2-oxo-3-oxazolidinyl)phosphinic chloride to give butenolide III. In the rat dermal vascular permeability assay, 100 mg III/kg i.p. gave >90% inhibition with resp. to serotonin, histamine, and bradykinin.

ACCESSION NUMBER: 1987:176155 HCAPLUS
DOCUMENT NUMBER: 106:176155
TITLE: N-phenyl- and N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4-(substituted anilino)-3-furancarboxamides as antiallergy agents
INVENTOR(S): Georgiev, Vassil S.; Mack, Robert A.
PATENT ASSIGNEE(S): Pennwalt Corp., USA
SOURCE: U.S., 4 pp. Cont.-in-part of U.S. Ser. No. 653,254.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4625040	A	19861125	US 1986-839298	19860313
US 4614810	A	19860930	US 1984-653254	19840924
CA 1240687	A1	19880816	CA 1985-488712	19850814
AU 8546298	A1	19860410	AU 1985-46298	19850819
AU 570572	B2	19880317		
IL 76194	A1	19880630	IL 1985-76194	19850826
ZA 8506907	A	19870325	ZA 1985-6907	19850910
JP 61078778	A2	19860422	JP 1985-203591	19850917
DK 8504295	A	19860325	DK 1985-4295	19850923
FI 8503648	A	19860325	FI 1985-3648	19850923
NO 8503737	A	19860325	NO 1985-3737	19850923
JP 62265278	A2	19871118	JP 1987-45401	19870302
CA 1254222	A1	19890516	CA 1987-531018	19870303
EP 237028	A1	19870916	EP 1987-103431	19870310

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

PRIORITY APPLN. INFO.: US 1984-653254 A2 19840924
US 1986-839298 A 19860313

OTHER SOURCE(S): CASREACT 106:176155; MARPAT 106:176155

L10 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 106212-49-1P 106212-50-4P 106212-51-5P
106212-52-6P 106212-53-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as allergy inhibitor)
RN 106212-49-1 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-4-[(3-methylphenyl)amino]-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-50-4 HCAPLUS
CN 3-Furancarboxamide, 4-[(4-chlorophenyl)amino]-2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-51-5 HCAPLUS
CN 3-Furancarboxamide, 4-[(3,5-dimethoxyphenyl)amino]-2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-52-6 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-4-[[3-(trifluoromethyl)phenyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 106212-53-7 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-4-[(3-nitrophenyl)amino]-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L10 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 21 Mar 1987
GI



AB Title compds. I [R = H, R2; R1 = H, Me, Et; R2 = alkyl, piperonyl, benzimidazolonylpropyl, (CH2)nXR3; R3 = (substituted) Ph; n = 1-3; X = bond, O, S, NH, CO, CH:CH, CHR3] are prepared and shown to block histamine H3 receptors. 4-(4-Piperidinyl)-1H-imidazole reacted with cyclohexyl isothiocyanate to give 74% (aminothiocarbonyl)piperidinylimidazole II. II blocked H3 histamine receptors in vitro, and increased the renewal of depleted histamine in rat cerebral cortex in vivo.

ACCESSION NUMBER: 1987:84602 HCAPLUS
DOCUMENT NUMBER: 106:84602
TITLE: 4-Imidazolylpiperidines and their H3 histamine receptor antagonist activity
INVENTOR(S): Arrang, Jean Michel; Garbarg, Monique; Lancelot, Jean Charles Maurice; Lecomte, Jeanne Marie; Robba, Max Fernand; Schwartz, Jean Charles
PATENT ASSIGNEE(S): Institut National de la Sante et de la Recherche Medicale (INSERM), Fr.; Universite de Caen; Societe Civile Bioprojet
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 197840	A1	19861015	EP 1986-400639	19860325
EP 197840	B1	19900801		
R: BE, CH, DE, FR, GB, IT, LI, LU, NL				
FR 2579596	A1	19861003	FR 1985-4496	19850326
FR 2579596	B1	19871120		
US 4707487	A	19871117	US 1986-840956	19860317
JP 61267574	A2	19861127	JP 1986-64994	19860325
JP 07068239	B4	19950726		
ES 553351	A1	19870316	ES 1986-553351	19860325

PRIORITY APPLN. INFO.: FR 1985-4496 A 19850326
OTHER SOURCE(S): CASREACT 106:84602; MARPAT 106:84602
IT **106243-38-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as histamine receptor antagonist)
RN 106243-38-3 HCAPLUS
CN 1-Piperidinecarboxamide, N-(2-phenylcyclopropyl)-4-[1-[[(2-phenylcyclopropyl)amino]carbonyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

L10 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 21 Mar 1987
GI



AB Treatment of furancarboxylic acids I and II (R = H, 3-NO2, 2-OMe, 3-CF3, 3-Me, 4-Br) with N,N-bis(2-oxo-3-oxazolidinyl)phosphinic chloride and an appropriate aromatic amine in the presence of Et3N resulted in a novel 3(2H)-furanone-2(5H)-furanone rearrangement that led to the facile preparation of new γ-lactone amides III [R1 = 3-Me, 4-Cl, 3-CF3, 3-NO2, 3,5-(OMe)2] and IV (R1 = 4-Cl, 4-Me, H, 3-CF3, 3-NO2, 4-OMe, 2-Me2CH; R2 = H,Me) resp. The mol. structure of IV (R = R2 = H, R1 = 4-Me) was determined by x-ray crystal structure anal. III and IV exerted moderate to potent antiallergic activity when tested in the dermal vascular permeability and active anaphylaxis assays in rats.

ACCESSION NUMBER: 1987:84304 HCAPLUS
DOCUMENT NUMBER: 106:84304
TITLE: A novel 3(2H)-furanone-2(5H)-furanone rearrangement
AUTHOR(S): Mack, Robert A.; Georgiev, Vassil St.
CORPORATE SOURCE: Pharm. Div., Pennwalt Corp., Rochester, NY, 14623, USA
SOURCE: Journal of Organic Chemistry (1987), 52(3), 477-8
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:84304
IT **106212-49-1P 106212-50-4P 106212-51-5P 106212-52-6P 106212-53-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 106212-49-1 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-4-[(3-methylphenyl)amino]-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 106212-50-4 HCAPLUS
CN 3-Furancarboxamide, 4-[(4-chlorophenyl)amino]-2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-51-5 HCAPLUS
CN 3-Furancarboxamide, 4-[(3,5-dimethoxyphenyl)amino]-2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-52-6 HCAPLUS
CN 3-Furancarboxamide, 2,5-dihydro-2-oxo-N-(2-phenylcyclopropyl)-4-[[3-(trifluoromethyl)phenyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106212-53-7 HCAPLUS

L10 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3-Furancarboxamide, 2,5-dihydro-4-[(3-nitrophenyl)amino]-2-oxo-N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 May 1985
AB Principal component anal. of the Rf values for 596 basic and neutral drugs in 4 eluent mixts. provided a significant 2-component model which explained 77% of the total variance. Each drug was characterized on a plane by 2 principal component scores. The loading plot shows that 3 eluent mixts. are clustered into the same group providing similar information. For identification of unknowns, the method provided a drastic reduction of the range of possibilities to a few candidates.

ACCESSION NUMBER:	1985:154850 HCAPLUS
DOCUMENT NUMBER:	102:154850
TITLE:	Application of principal components analysis to TLC data for 596 basic and neutral drugs in four eluent systems
AUTHOR(S):	Musumarra, Giuseppe; Scarlata, Giuseppe; Romano, Guido; Clementi, Sergio; Wold, Svante
CORPORATE SOURCE:	Ist. Dip. Chim. Chim. Ind., Univ. Catania, Catania, 95125, Italy
SOURCE:	Journal of Chromatographic Science (1984), 22(12), 538-47 CODEN: JCHSBZ; ISSN: 0021-9665
DOCUMENT TYPE:	Journal
LANGUAGE:	English

IT 2829-19-8
RL: ANT (Analyte); ANST (Analytical study)
(chromatog. of, thin-layer, principal component anal. in)
RN 2829-19-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Jan 1985
GI



I

AB The title compds. [I; R = alkyl; R1 = (un)substituted saturated or unsatd. carbocyclyl; n, m = 1-4] were prepared Thus, 3,4-(MeO)2C6H3CH2CO2H was treated with (PhO)2P(O)N3 and Et3N to give 3,4-(MeO)2C6H3CH2NCO which was condensed without isolation with 5-fluorouracil to give I [R1 = 3,4-(MeO)2C6H3, n = 1, m = 0] (II). In mice infected with Lewis lung carcinoma 200 mg II/kg orally 3 times per wk gave a 105% increase in life span.

ACCESSION NUMBER:	1985:6062 HCAPLUS
DOCUMENT NUMBER:	102:6062
TITLE:	1-(N-Substituted carbamoyl)-5-fluorouracil derivatives with anticancer activity
INVENTOR(S):	Ozaki, Shoichiro; Hoshiko, Tomonori; Ogasawara, Tomio
PATENT ASSIGNEE(S):	Japan
SOURCE:	Ger. Offen., 28 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3301107	A1	19840719	DE 1983-3301107	19830114
US 4497815	A	19850205	US 1983-455863	19830105
DE 3347795	A1	19850801	DE 1983-3347795	19830114
DE 3347795	C2	19900517		

PRIORITY APPLN. INFO.:	DE 1983-3301107 19830114
OTHER SOURCE(S):	CASREACT 102:6062; MARPAT 102:6062

IT 86655-34-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and neoplasm inhibitor activity of)
RN 86655-34-7 HCAPLUS
CN 1(2H)-Pyrimidinecarboxamide, 5-fluoro-3,4-dihydro-2,4-dioxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI



CONH(CH2)m(CHR1)nR I

AB I [R = (substituted) aryl or aralkyl, (unsatd.) cycloalkyl, etc.; R1 = alkyl; m, n = 0-4] were prepared Thus, heating a mixture of 3.9 g 5-fluorouracil, 6.27 g 3,4,5-(MeO)3C6H2NCO, 10 mL pyridine at 90° for 2 h gave 4.8 g I [R = 3,4,5-(MeO)3C6H2, m = n = 0]. Life-prolongation rates for I at 60 and 100 mg single doses were >10 and >30%, resp., in mice implanted with 10 Lewis lung carcinoma cells.
ACCESSION NUMBER: 1983:470761 HCAPLUS
DOCUMENT NUMBER: 99:70761
TITLE: Anti-cancer 5-fluorouracils
PATENT ASSIGNEE(S): Ozaki, Shoichiro, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58072569	A2	19830430	JP 1981-173590	19811027
PRIORITY APPLN. INFO.:			JP 1981-173590	19811027

OTHER SOURCE(S): CASREACT 99:70761
IT 86655-34-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and anticancer activity of)
RN 86655-34-7 HCAPLUS
CN 1(2H)-Pyrimidinecarboxamide, 5-fluoro-3,4-dihydro-2,4-dioxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 34 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
AB EX-4883 [5-oxo-N-(d-trans-2-phenylcyclopropyl)-l-2-pyrrolidinecarboxamide] (I) [2829-19-8], a potent monoamine oxidase inhibitor in vivo, and tranylcypromine [3721-28-6] in equimolar concns. showed similar results on rat and cat blood pressures, on cat nictitating membrane, and on rat Langendorff heart. Although tranylcypromine showed a more potent inotropic effect than I in isolated rat atria, bioactivation of I by a soluble fraction component of rat liver homogenate shifted I activity towards that of tranylcypromine. These results, and the fact that I inhibited monoamine oxidase [9001-66-5] in vitro only after activation by liver homogenate, suggested that I was biotransformed to an active metabolite having similar pharmacol. effects to those of tranylcypromine.
ACCESSION NUMBER: 1973:105939 HCAPLUS
DOCUMENT NUMBER: 78:105939
TITLE: Role of biotransformation on the pharmacology of the monoamine oxidase inhibitor N-(d-trans-2-phenylcyclopropyl)-l-2-pyrrolidin-5-onecarboxamide (EX'-4883)
AUTHOR(S): Lowe, M. C.; Horita, A.
CORPORATE SOURCE: Sch. Med., Univ. Washington, Seattle, WA, USA
SOURCE: European Journal of Pharmacology (1973), 21(1), 46-52
CODEN: EJPHAZ; ISSN: 0014-2999
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 2829-19-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of, tranylcypromine in relation to)
RN 2829-19-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
AB The role of metabolism in the activation of monoamine oxidase (MAO) inhibitors was studied. One of these [5-oxo-N-(D-trans-2-phenylcyclopropyl)-L-2-pyrrolidinecarboxamide] is inactive in vitro; when incubated with the soluble fraction of rat liver (and to a lesser extent that of brain, kidney, and skeletal muscle) 2-phenylcyclopropylamine (tranylcypromine) was liberated, which inhibited MAO. It is assumed that a similar transformation is responsible for the activation of this compound in the intact animal. An irreversible MAO inhibitor, phenelzine, is also a substrate for MAO. Expts. in vivo, and in vitro demonstrated the appearance of phenylacetic acid, supporting the hypothesis that MAO is inhibited by N2H4 liberated during the dehydrazination of this compound
ACCESSION NUMBER: 1970:518743 HCAPLUS
DOCUMENT NUMBER: 73:118743
TITLE: Role of metabolism in the action of some monoamine oxidase inhibitors
AUTHOR(S): Horita, Akira; Clineschmidt, B. V.; McMonigle, J. J.
CORPORATE SOURCE: Dep. of Pharmacol., Univ. of Washington, Seattle, WA, USA
SOURCE: Present Status Psychotropic Drugs, Proc. Int. Congr. Coll. Int. Neuro-Psychopharmacol, 6th (1969), Meeting Date 1968, 94-7
CODEN: 22AKA8
DOCUMENT TYPE: Conference
LANGUAGE: English
IT 23887-48-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of, monoamine oxidase inhibition in relation to)
RN 23887-48-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (7CI, 8CI) (CA INDEX NAME)



L10 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
AB L-trans-(+)-5-Oxo-N-(2-phenylcyclopropyl)-2-pyrrolidine carboxamide (E X 4883) was an active monoamine oxidase inhibitor only after bioconversio n to an active metabolite. The enzyme responsible for the activation was found in the soluble fraction (100,000 + g supernatant) of the cell and was highly active in rat liver, kidney, and brain tissues. The enzyme converted EX 4883 into tranylcypromine and pyrrolidone carboxylic acid, with a pH optimum of 7-8; the enzyme was not inhibited by KCN or anaerobic conditions. This biotransformation of EX 4883 by a soluble fraction enzyme represents a new mechanism for drug transformation.
ACCESSION NUMBER: 1970:20210 HCAPLUS
DOCUMENT NUMBER: 72:20210
TITLE: Bioactivation of L-trans-(+)-5-oxo-N-(2-phenylcyclopropyl)-2-pyrrolidinecarboxamide (EX 4883) into a monoamine oxidase inhibitor by a soluble fraction enzyme system
AUTHOR(S): McMonigle, J. J.; Horita, A.
CORPORATE SOURCE: Sch. of Med., Univ. of Washington, Seattle, WA, USA
SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1969), 178(1), 53-61
CODEN: AIPTAX; ISSN: 0003-9780
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 2829-19-8
RL: BIOL (Biological study)
(enzymic transformation of, monoamine oxidase inhibition in relation to)
RN 2829-19-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
AB Unavailable
ACCESSION NUMBER: 1968:113175 HCAPLUS
DOCUMENT NUMBER: 68:113175
TITLE: Bioactivation of 5-oxo-N-(D-trans-2-phenylcyclopropyl)-L-2-pyrrolidinecarboxamide (EX 4883) into a potent inhibitor of monoamine oxidase
AUTHOR(S): McMonigle, John J.
CORPORATE SOURCE: Univ. of Washington, Seattle, WA, USA
SOURCE: (1968) 127 pp. Avail.: 67-14,192
From: Diss. Abstr. B 1968, 28(7), 2979
DOCUMENT TYPE: Dissertation
LANGUAGE: English
IT 2829-19-8
RL: BIOL (Biological study)
(monoamine oxidase inhibition by)
RN 2829-19-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
AB (see Brit. 961, 313, CA 61, 6954f). Separation of D-trans-2-phenylcyclopropylamine (I), and L-trans-2-phenylcyclopropylamine (II), from the DL-mixture of these amines is carried out using L-5-pyrrolidinone-2-carboxylic acid (III). The title compds. possess monoamide oxidase-inhibitory properties. To a solution of 5.2 g. III in 80 ml. EtOH containing 5% MeOH at room temperature is added a solution of 5.3 g. DL-trans-2-phenylcyclopropylamine in 20 ml. EtOH containing 5% MeOH. The mixture is chilled in an ice bath until crystallization is complete, the salt removed by filtration, washed with Et2O and dried to yield 4.6 g. of A salt (IV), m. 152-4°. Crystallization from MeCN gives 3.8 g. of pure IV, m. 150-1°, [α]25D -59.67° (H2O). Liberation of II, [α]25D - 117.5° (dioxane), from IV is done with aqueous NaOH solution After removal of IV, the filtrate is diluted with Et2O and 4.2 g. B salt (V), m. 118-21° is obtained. Crystallization of V from MeCN gives 3.9 g. purified V, m. 119-20°, [α]25D 23.27° (H2O).
Treatment of purified V with NaOH solution releases strongly enriched I, [α]25D 81.4° (dioxane). To a solution of 5.4 g. III, and 5.6 g. I in 35 ml. 19:1 EtOH-MeOH is added a solution of 9.1 g. dicyclohexylcarbodiimide (VI) in 15 ml. 19:1 EtOH-MeOH. The mixture is stirred overnight at ambient temperature, the dicyclohexylurea removed by filtration, the urea washed with MeCN and the filtrate concentrated to yield 12.9 g. residue which was dissolved in 15 ml. hot MeCN. The solid isolated after crystallization is dried to yield 7.8 g. of crude product, which is crystallized from hot H2O to give 3.6 g. D-N-(trans-2-phenylcyclopropyl)-L-5-pyrrolidone-2-carboxamide, m. 144-7°, [α]25D 104.28° (HCONMe2). In the same manner, 4 g. of L-N-(trans-2-phenylcyclopropyl)-L-5-pyrrolidinone-2-carboxamide, m. 136-7°, [α]25D -110.56° (HCONMe2), is obtained from the reaction of 7.0 g. II, 7.2 g. III, and 11.5 g. VI.
ACCESSION NUMBER: 1967:104804 HCAPLUS
DOCUMENT NUMBER: 66:104804
TITLE: Phenylcyclopropyl amides
INVENTOR(S): Biel, John H.
PATENT ASSIGNEE(S): Lakeside Laboratories, Inc.
SOURCE: Fr., 3 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 87352		19660729	FR	
PRIORITY APPLN. INFO.:			US	19610426

IT 2829-19-8P 2829-20-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 2829-19-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 2829-20-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)-, stereoisomer (8CI) (CA INDEX NAME)



L10 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 22 Apr 2001
AB Title compds. are prepared by treating a phenylcyclopropylamine with an organic halide or an amino acid (the intermediate in the latter case is dehydrated in situ using dicyclohexylcarbodiimide. E.g., 27 g. trans-phenylcyclopropylamine added at 0-5° to the reaction mixture of 25 g. isonicotinic acid, 20.3 g. Et3N, and 23.8 g. ClCO2Et in CH2Cl2 gave 4.2 g. N-isonicotinoyl-trans-clopropylamine m. 142°. Similarly prepared were the following (compound, % yield, and m.p. given): N-(trans-2-phenylcyclopropyl)-p-chlorophenoxyacetamide, 53, 83-5°; N-(trans-2-phenylcyclopropyl)-2-piperidinoacetamide, 100, -; N-(trans-2-phenylcyclopropyl)-2-chloroacetamide, 72, 73-4°; N-(trans-2phenylcyclopropyl)acrylamide, 83, 77°; trans-N-phenylcyclopropyl-2-(N-benzyl-N-propargylamino)acetamide, 42, -; N-(4-hydroxybutyryl)-trans-phenylcyclopropylamine, 56, 83-5°; N-(3,4,5-trimethoxybenzoyl)-trans-phenylcyclopropylamine, 68, 192-4°; N-trans-2-phenylcyclopropyl-4-(N-piperidyl)butyramide, 68.5,-(b0-06 190°, n20D 1.5447); N-trans-2-phenylcyclopropyl-4-chlorobutyramide, 71.5, 74°; N-(N-methyl)pipecoloyl-trans-phenylcyclopropylamine,-, -; L-phenylalanyl-d-trans-phenylcyclopropylamine, -, 91°, N-trans-2-phenylcyclopropyl-L-5-pyrrolidone-2-carboxamide, 82, -; D-N-(trans-2-phenylcyclopropyl)-L-5-pyrrolidone-2-carboxamide, -, 144-7°; L-N-(trans-2-phenylcyclopropyl)-L-5-pyrrolidone-2-carboxamide.
ACCESSION NUMBER: 1965:454588 HCAPLUS
DOCUMENT NUMBER: 63:54588
ORIGINAL REFERENCE NO.: 63:9922a-d
TITLE: Phenylcyclopropyl amides
INVENTOR(S): Beil, John H.
PATENT ASSIGNEE(S): Colgate-Palmolive Co.
SOURCE: 5 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3192229		19650629	US	19610426
PRIORITY APPLN. INFO.:			US	19610426

IT 2808-87-9, Isonicotinamide, N-(2-phenylcyclopropyl)-, trans-
23887-48-1, 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)-, L,L-trans-
(preparation of)
RN 2808-87-9 HCAPLUS
CN 4-Pyridinecarboxamide, N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 23887-48-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 5-oxo-N-(2-phenylcyclopropyl)- (7CI, 8CI) (CA INDEX NAME)

L10 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L10 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 22 Apr 2001
AB The monoamine oxidase (MAO)-inhibitory activity of numerous analogs and ring-homologs of 2-phenylcyclopropylamine, and related compds., as measured in vivo by potentiation of tryptamine convulsions, has been determined The results indicated that the structural requirements for potent in vivo MAO-inhibitory activity in this class of compds. are: (1) a cyclopropane ring, (2) an amino group attached directly to the cyclopropane ring, and (3) a 2-substituent containing an aromatic moiety. On the basis of an examination of mol. models of cyclopropylamine derivs. and other types of MAO-inhibitors, possible modes of interaction of these compds. with MAO have been considered.
ACCESSION NUMBER: 1963:403209 HCAPLUS
DOCUMENT NUMBER: 59:3209
ORIGINAL REFERENCE NO.: 59:504h,505a
TITLE: 2-Substituted cyclopropylamines. II. Effect of structure upon monoamine oxidase-inhibitory activity as measured in vivo by potentiation of tryptamine convulsions
AUTHOR(S): Zirkle, Charles L.; Kaiser, Carl; Tedeschi, David H.; Tedeschi, Ralph E.; Burger, Alfred
CORPORATE SOURCE: Smith Kline & French Labs., Philadelphia, PA
SOURCE: Journal of Medicinal & Pharmaceutical Chemistry (1962), 5, 1265-84
CODEN: JMPCAS; ISSN: 0095-9065
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 2808-87-9, Isonicotinamide, N-(2-phenylcyclopropyl)-, trans- (monoamine oxidase-inhibitory activity of)
RN 2808-87-9 HCAPLUS
CN 4-Pyridinecarboxamide, N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 41 OF 41 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 22 Apr 2001
GI For diagram(s), see printed CA Issue.
AB A series of derivs. (I, II) of 2-phenylcyclopropylamine and analogs, 2-arylcyclopropanecarboxhydrazides, -carboxamides, -methyl-amines, -carboxylic acids, esters, and chlorides has been prepared in order to study relationships between chemical structure and monoamine oxidase-inhibiting activity.
ACCESSION NUMBER: 1963:403208 HCAPLUS
DOCUMENT NUMBER: 59:3208
ORIGINAL REFERENCE NO.: 59:504f-h
TITLE: 2-Substituted cyclopropylamines. I. Derivatives and analogs of 2-phenylcyclopropylamine
AUTHOR(S): Kaiser, Carl; Lester, Bruce M.; Zirkle, Charles L.; Burger, Alfred; Davis, Charles S.; Delia, Thomas J.; Zirngibl, Ludwig
CORPORATE SOURCE: Smith Kline & French Labs., Philadelphia, PA
SOURCE: Journal of Medicinal & Pharmaceutical Chemistry (1962), 5, 1243-65
CODEN: JMPCAS; ISSN: 0095-9065
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 59:3208
IT 2808-87-9, Isonicotinamide, N-(2-phenylcyclopropyl)-, trans- (preparation of)
RN 2808-87-9 HCAPLUS
CN 4-Pyridinecarboxamide, N-(2-phenylcyclopropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	212.97	384.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-30.00	-30.00

STN INTERNATIONAL LOGOFF AT 17:01:12 ON 01 MAR 2006

10636001RTR

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS 15	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 16	FEB 22	Status of current WO (PCT) information on STN
NEWS 17	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 18	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 19	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 20	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 21	FEB 28	TOXCENTER reloaded with enhancements
NEWS 22	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:31:47 ON 01 MAR 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:32:22 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0
DICTIONARY FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10636001RTR.str





10636001RTR

chain nodes :
4 5 6 7 8 11
ring nodes :
1 2 3
chain bonds :
2-5 3-4 5-6 5-11 6-7 6-8
ring bonds :
1-2 1-3 2-3
exact/norm bonds :
1-2 1-3 2-3 2-5 5-6 5-11 6-7 6-8
exact bonds :
3-4

G1:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:CLASS 7:Atom 8:CLASS 11:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:32:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 140936 TO ITERATE

1.4% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2796571 TO 2840869
PROJECTED ANSWERS: 3356 TO 5100

L2 3 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:32:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2818331 TO ITERATE

33.1% PROCESSED 933145 ITERATIONS 1387 ANSWERS

35.5% PROCESSED 1000000 ITERATIONS 1453 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.20

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2818331 TO 2818331
PROJECTED ANSWERS: 3904 TO 4286

L3 1453 SEA SSS FUL L1

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:end

=>
Uploading C:\Program Files\Stnexp\Queries\10636001s2.str





chain nodes :
4 5 6 7 8 11
ring nodes :
1 2 3
chain bonds :
2-5 3-4 5-6 5-11 6-7 6-8
ring bonds :
1-2 1-3 2-3
exact/norm bonds :
1-2 1-3 2-3 2-5 5-6 5-11 6-7 6-8
exact bonds :
3-4

G1:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:CLASS 7:Atom 8:CLASS 11:CLASS
Generic attributes :
4:
Saturation : Unsaturated

Element Count :
Node 7: Limited
N,N1
C,C4

L4 STRUCTURE UPLOADED

10636001RTR

=> d l4
L4 HAS NO ANSWERS
L4 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 14:35:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 140936 TO ITERATE

1.4% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2796571 TO 2840869
PROJECTED ANSWERS: 2106 TO 3530

L5 2 SEA SSS SAM L4

=>
Uploading C:\Program Files\Stnexp\Queries\10636001s3.str



chain nodes :
4 5 6 9 22 23 24
ring nodes :
1 2 3 11 12 13 14 15 16 17 18 19 20 21
chain bonds :
2-4 3-11 4-5 4-9 5-6 5-17 22-23 23-24
ring bonds :
1-2 1-3 2-3 11-12 11-16 12-13 13-14 14-15 15-16 17-18 17-21 18-19 19-20 20-21
exact/norm bonds :
1-2 1-3 2-3 2-4 4-5 5-6 17-18 17-21 18-19 19-20 20-21 23-24
exact bonds :

10636001RTR

3-11 4-9 5-17 22-23
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16

G1:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:CLASS 5:CLASS 6:CLASS 9:CLASS 11:CLASS 12:Atom 13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:CLASS
23:CLASS 24:Atom 27:CLASS

L6 STRUCTURE UPLOADED

=> d 16
L6 HAS NO ANSWERS
L6 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l6
SAMPLE SEARCH INITIATED 14:39:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 200 TO 800
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s l6 full
FULL SEARCH INITIATED 14:40:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 526 TO ITERATE

100.0% PROCESSED 526 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L8 3 SEA SSS FUL L6

=> fil hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	338.72	338.93

FILE 'HCAPLUS' ENTERED AT 14:40:09 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Mar 2006 VOL 144 ISS 10
FILE LAST UPDATED: 28 Feb 2006 (20060228/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l8
L9 2 L8

=> d ed abs ibib hitstr 1-2

L9 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Feb 2004
GI



AB The present invention relates to acylated arylcycloalkylamines of the formula (I) including N-(trans-2-phenylcyclopropyl)carboxamides [wherein R1, R2 = each (un)substituted Ph, 1- or 2-naphthyl, or 5- to 10-membered, aromatic, monocyclic or bicyclic heterocycle containing one or more heteroatoms selected from the group consisting of N, O and S; n = an integer of 1-4]. These compds. upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. They are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. The diseases also include for the treatment of stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, peripheral artery occlusive disease, endothelial dysfunction, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance or a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or of women taking contraceptives. For example, N-(trans-2-phenylcyclopropyl)-3-amino-5-methylpyrazine-2-carboxamide and N-(trans-2-phenylcyclopropyl)-2,5-dimethyl-1-(thiophen-2-ylmethyl)-1H-pyrrole-3-carboxamide inhibited the activation of transcription of human endothelial nitric oxide synthetase in primary human umbilical vein code cells (HUVEC) with EC50 of 0.060 and <0.01 μM, resp.

ACCESSION NUMBER: 2004:117248 HCAPLUS
DOCUMENT NUMBER: 140:181465
TITLE: Preparation of acylated arylcycloalkylamines and their use as pharmaceuticals for treatment of cardiovascular disorders
INVENTOR(S): Strobel, Hartmut; Wohlfart, Paulus; Below, Peter
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1388535	A1	20040211	EP 2002-17587	20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

L9 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CA 2494628	AA	20040219	CA 2003-2494628	20030724
WO 2004014842	A1	20040219	WO 2003-EP8104	20030724
WO 2004014842	C1	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003250159	A1	20040225	AU 2003-250159	20030724
EP 1529031	A1	20050511	EP 2003-784056	20030724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013271	A	20050621	BR 2003-13271	20030724
JP 2005534706	T2	20051117	JP 2004-526766	20030724
US 2004082628	A1	20040429	US 2003-636001	20030807
NO 2005001110	A	20050301	NO 2005-1110	20050301
PRIORITY APPLN. INFO.:			EP 2002-17587 A	20020807
			US 2002-432312P P	20021210
			WO 2003-EP8104 W	20030724

OTHER SOURCE(S): MARPAT 140:181465
IT **658683-80-8P 658683-85-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylated arylcycloalkylamines as regulators of transcription of endothelial nitric oxide synthase gene and pharmaceuticals for treatment of cardiovascular disorders)
RN 658683-80-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2,5-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-1-(2-thienylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-85-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2,5-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-1-(4-pyridinylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 17 Aug 2001
GI



AB The title compds. [I; A, B = C, N so that ring X = pyrrole, pyrazole or imidazole (wherein when A = N, the group CONR1R2 is attached to atom C-3 and R5 does not exist; and when A = C, one of CONR1R2 and R5 is attached to A and the other to atom C-3; and when B = C, two R4 groups attached to B and atom C-5, resp., form a fused 6-membered heteroaryl); f = 0-1; g = 1-2; R1, R2 = H, alkyl, heterocycloalkyl, etc.; R2 together with R1 or R5 forms a 5-6 membered heterocyclo; R3 = H, alkyl, aryl, etc.; R4 is attached to atom C-5 and optionally B and is H, alkyl, aryl, etc.; R5 is attached to A or atom C-3 and is H, alkyl, aryl, etc.; R5 together with R2 forms a heterocyclo], useful as cannabinoid receptor modulators (no data given) for treating respiratory and non-respiratory leukocyte-activation associated diseases, were prepared Thus, reacting the acid chloride II [X = Cl] (multi-step synthesis given) with 2,2,6,6-tetramethylcyclohexylamine afforded the pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamide II [X = 2,2,6,6-tetramethylcyclohexylamino].

ACCESSION NUMBER: 2001:597958 HCAPLUS
DOCUMENT NUMBER: 135:166827
TITLE: Preparation of 1H-indole-3-carboxamides, 1H-indazole-3-carboxamides, 1H-pyrido[4,3-b]indol-1-ones and pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamides as cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
INVENTOR(S): Leftheris, Katerina; Zhao, Rulin; Chen, Bang-Chi; Kiener, Peter; Wu, Hong; Pandit, Chennagiri R.; Wrobleski, Stephen; Chen, Ping; Hynes, John, Jr.; Longphre, Malinda; Norris, Derek J.; Spergel, Steven; Tokarski, John
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; et al.
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058869	A2	20010816	WO 2001-US4131	20010208
WO 2001058869	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

L9 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2399791	AA	20010816	CA 2001-2399791		20010208
AU 2001034958	A5	20010820	AU 2001-34958		20010208
EP 1254115	A2	20021106	EP 2001-907144		20010208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004502642	T2	20040129	JP 2001-558420		20010208
PRIORITY APPLN. INFO.:			US 2000-181818P	P	20000211
			WO 2001-US4131	W	20010208

OTHER SOURCE(S): MARPAT 135:166827

IT 354569-58-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-indole-3-carboxamides, 1H-indazole-3-carboxamides, 1H-pyrido[4,3-b]indol-1-ones and pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamides as cannabinoid receptor modulators for treating respiratory and non-respiratory diseases)

RN 354569-58-7 HCAPLUS

CN 1H-Indole-3-carboxamide, 5-fluoro-7-methoxy-2-methyl-1-[2-(4-morpholinyl)ethyl]-N-[(1S,2S)-2-phenylcyclopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10636001RTR

=> fil reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 15.28 | 354.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | -1.50 | -1.50

FILE 'REGISTRY' ENTERED AT 14:41:26 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0
DICTIONARY FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10636001s4.str





chain nodes :
4 5 6 9 11
ring nodes :

10636001RTR

1 2 3 12 13 14 15 16
chain bonds :
2-4 3-11 4-5 4-9 5-6 5-12
ring bonds :
1-2 1-3 2-3 12-13 12-16 13-14 14-15 15-16
exact/norm bonds :
1-2 1-3 2-3 2-4 4-5 5-6 12-13 12-16 13-14 14-15 15-16
exact bonds :
3-11 4-9 5-12

G1:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:CLASS 5:CLASS 6:CLASS 9:CLASS 11:CLASS 12:Atom 13:Atom
14:Atom 15:Atom 16:Atom

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l10
SAMPLE SEARCH INITIATED 14:43:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1065 TO ITERATE

100.0% PROCESSED 1065 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 19343 TO 23257
PROJECTED ANSWERS: 9 TO 360

L11 9 SEA SSS SAM L10

=> s l10 full
FULL SEARCH INITIATED 14:43:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22181 TO ITERATE

100.0% PROCESSED 22181 ITERATIONS 198 ANSWERS
SEARCH TIME: 00.00.01

L12 198 SEA SSS FUL L10

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.82	522.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

FILE 'HCAPLUS' ENTERED AT 14:43:22 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Mar 2006 VOL 144 ISS 10
FILE LAST UPDATED: 28 Feb 2006 (20060228/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l12
L13 14 L12

=> d ed abs ibib hitstr 1-14

L13 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 01 Apr 2005
GI



I

AB Preparation of fungicidal compds. I (X = O, S; RING = Ph, thienyl; Het = 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from O, N, S, the ring being substituted by one to four groups R4; R1 = H, optionally substituted (C1-4)alkyl, formyl, optionally substituted (C1-4)alkylC(:O), optionally substituted (C1-4)alkylC(:O)O, optionally substituted (C1-4)alkoxy(C1-4)alkyl, optionally substituted allyl, optionally substituted propargyl or optionally substituted allenyl; R2 = independently, halo, optionally substituted (C1-4)alkyl, optionally substituted (C1-4)alkoxy or optionally substituted (C1-4)alkoxy(C1-4)alkyl; R3 = (CRaRb)m-Cy-(CRcRd)n-Y; R4 = independently, selected from halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy(C1-3)alkyl and cyano; Ra, Rb, Rc, Rd = independently, H, optionally substituted (C1-4)alkyl; Cy is an optionally substituted carbocyclic or heterocyclic 3-7 membered ring which may be saturated, unsatd. or aromatic and which optionally contains a silicon atom as a ring member; (CRaRb)m and (CRcRd)n may be bound either to the same carbon or silicon atom of Cy or to different atoms separated by 1, 2 or 3 ring members; Y = silyloxy etc.), useful as fungicides in agriculture (activity given), is described. Thus, reaction of N-methyl-3-difluoromethyl-4-chlorocarbonylpyrazole with 1,1-dimethyl-3-(2'-amino)phenylsilacyclohexane (preparation given) gave title compound which was used as fungicides (activity given).

ACCESSION NUMBER: 2005:283496 HCAPLUS
DOCUMENT NUMBER: 142:336464
TITLE: Preparation of heterocyclic substituted silicon compounds with microbiocidal activity
INVENTOR(S): Ehrenfreund, Josef; Lamberth, Clemens; Tobler, Hans; Walter, Harald
PATENT ASSIGNEE(S): Syngenta Participations Ag, Switz.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005028485	A1	20050331	WO 2004-EP10009	20040908
WO 2005028485	C1	20050609		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

L13 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-22012 A 20030919
OTHER SOURCE(S): MARPAT 142:336464
IT 848785-60-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic substituted silicon compds. with microbiocidal activity)
RN 848785-60-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[2-[(1R,2S)-2-(trimethylsilyl)cyclopropyl]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Jul 2004
GI



I II

AB The title compds. [I; Het = (un)substituted 5-6 membered heterocyclic ring; R1 = H, CHO, CO(alkyl), CO2(alkyl), alkoxyalkylene, CO(alkylenoxy)alkyl, propargyl, allenyl; R2-R5 = H, halo, Me, CF3; R6 = halo, Me, CF3; R7 = (Z)mC.tplbond.CY1, (Z)mCY1:CY2Y3, trialkylsilyl; X = O, S; Y1-Y3 = H, halo, (un)substituted alkyl alkenyl, alkynyl, cycloalkyl, trialkylsilyl; Z = (un)substituted alkylene; m = 0-1; n = 0-2], useful in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi, were prepared Thus, reacting 2-amino-4'-ethynylbiphenyl with 1-methyl-3-trifluoromethyl-4-chlorocarbonylpyrazole in the presence of pyridine in THF afforded 70% II which showed excellent fungicidal activity (biol. data given).

ACCESSION NUMBER: 2004:565219 HCAPLUS
DOCUMENT NUMBER: 141:123619
TITLE: Preparation of biphenyl derivatives and their use as fungicides
INVENTOR(S): Ehrenfreund, Josef; Lamberth, Clemens; Tobler, Hans; Walter, Harald
PATENT ASSIGNEE(S): Syngenta Participations Ag, Switz.
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058723	A1	20040715	WO 2003-EP14248	20031215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2510528	AA	20040715	CA 2003-2510528	20031215

L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

EP 1575922	A1	20050921	EP 2003-813891	20031215

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003016879	A	20051025	BR 2003-16879	20031215
NO 2005003558	A	20050725	NO 2005-3558	20050720

PRIORITY APPLN. INFO.: GB 2002-30155 A 20021224
WO 2003-EP14248 W 20031215
OTHER SOURCE(S): MARPAT 141:123619
IT 723747-89-5P 723747-91-9P 723747-93-1P
723747-94-2P 723747-96-4P 723747-98-6P
723748-00-3P 723748-02-5P 723748-04-7P
723748-06-9P 723748-08-1P 723748-10-5P
723748-12-7P 723748-14-9P 723748-16-1P
723748-18-3P 723748-20-7P 723748-22-9P
723748-24-1P 723748-26-3P 723748-28-5P
723748-30-9P 723748-32-1P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenyl derivs. and their use as fungicides)
RN 723747-89-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-ethynyl[1,1'-biphenyl]-2-yl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723747-91-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[4'-[(trimethylsilyl)ethynyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 723747-93-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(chloroethynyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723747-94-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[4'-(3,3,3-trifluoro-1-propynyl)[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 723747-96-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(2,2-difluoroethenyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 723747-98-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(2,2-dichloroethenyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-00-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(2,2-dibromoethenyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 723748-02-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4'-(trifluoroethenyl)[1,1'-biphenyl]-2-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-04-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(1-chloroethenyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-06-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(2-chloro-3,3,3-trifluoro-1-propenyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 723748-08-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(3,3-dimethyl-1-butynyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-10-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4'-(1-propynyl)[1,1'-biphenyl]-2-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-12-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(3-fluoro-1-butynyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 723748-14-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(3-fluoro-3-methyl-1-butynyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-16-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4'-(4-methyl-1-pentynyl)[1,1'-biphenyl]-2-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[4'-(3,3-difluoro-1-butynyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-24-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(2-bromoethenyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-26-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4'-(2,3,3,3-tetrafluoro-1-propenyl)[1,1'-biphenyl]-2-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 723748-18-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[(1-fluorocyclopentyl)ethynyl][1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-20-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(3-methoxy-3-methyl-1-butynyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-22-9 HCAPLUS

L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 723748-28-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(2,2-dibromo-1-methylethenyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 723748-30-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[4'-[1-(trifluoromethyl)ethenyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 723748-32-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-(3-hydroxy-3-methyl-1-butynyl)[1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L13 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Jun 2004
GI



AB Title compds. [I; R = H, alkyl, haloalkyl; Z = alkenyl, alkynyl, haloalkenyl, haloalkynyl; X, Y = halo, cyano, NO2, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio; m, n = 0-4; A = 5-6 membered substituted heterocyclyl], were prepared Thus, 2'-amino-1,1'-biphenyl-4-carbaldehyde O-allyloxime (preparation given) and Et3N was treated with 4-difluoromethyl-2-methylthiazole-5-carbonyl chloride in PhMe at room temperature followed by stirring for 3 h at 50° to give 49.6% N-(4'-[(E)-[(allyloxy)imino]methyl]-1,1'-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide. The latter at 100 ppm gave 100% control of Venturia inaequalis.

ACCESSION NUMBER: 2004:509994 HCAPLUS
DOCUMENT NUMBER: 141:54333
TITLE: Preparation of biphenylcarboxamides as agricultural fungicides and insecticides
INVENTOR(S): Dunkel, Ralf; Elbe, Hans-Ludwig; Rieck, Heiko; Greul, Joerg Nico; Wachendorff-Neumann, Ulrike; Mauler-Machnik, Astrid; Dahmen, Peter; Kuck, Karl-Heinz; Loesel, Peter
PATENT ASSIGNEE(S): Bayer Cropscience AG, Germany
SOURCE: Ger. Offen., 70 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10258314	A1	20040624	DE 2002-10258314	20021213
WO 2004054982	A1	20040701	WO 2003-EP13498	20031201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,

L13 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1572663 A1 20050914 EP 2003-795860 20031201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003017290 A 20051108 BR 2003-17290 20031201
PRIORITY APPLN. INFO.: DE 2002-10258314 A 20021213
WO 2003-EP13498 W 20031201

OTHER SOURCE(S): MARPAT 141:54333
IT 705944-72-5P 705944-74-7P 705945-01-3P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenylcarboxamides as agricultural fungicides and insecticides)
RN 705944-72-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[1-[(cyclopropylmethoxy)imino]ethyl][1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 705944-74-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4'-[1-[(2-propenyloxy)imino]ethyl][1,1'-biphenyl]-2-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 705945-01-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4'-[1-[[(1-methyl-2-

L13 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
propenyl)oxy]imino]ethyl][1,1'-biphenyl]-2-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Feb 2004
GI



AB The present invention relates to acylated arylcycloalkylamines of the formula (I) including N-(trans-2-phenylcyclopropyl)carboxamides [wherein R1, R2 = each (un)substituted Ph, 1- or 2-naphthyl, or 5- to 10-membered, aromatic, monocyclic or bicyclic heterocycle containing one or more heteroatoms selected from the group consisting of N, O and S; n = an integer of 1-4]. These compds. upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. They are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. The diseases also include for the treatment of stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, peripheral artery occlusive disease, endothelial dysfunction, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance or a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or of women taking contraceptives. For example, N-(trans-2-phenylcyclopropyl)-3-amino-5-methylpyrazine-2-carboxamide and N-(trans-2-phenylcyclopropyl)-2,5-dimethyl-1-(thiophen-2-ylmethyl)-1H-pyrrole-3-carboxamide inhibited the activation of transcription of human endothelial nitric oxide synthetase in primary human umbilical vein code cells (HUVEC) with EC50 of 0.060 and <0.01 μM, resp.

ACCESSION NUMBER: 2004:117248 HCAPLUS
DOCUMENT NUMBER: 140:181465
TITLE: Preparation of acylated arylcycloalkylamines and their use as pharmaceuticals for treatment of cardiovascular disorders
INVENTOR(S): Strobel, Hartmut; Wohlfart, Paulus; Below, Peter
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1388535	A1	20040211	EP 2002-17587	20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

L13 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CA 2494628	AA	20040219	CA 2003-2494628	20030724
WO 2004014842	A1	20040219	WO 2003-EP8104	20030724
WO 2004014842	C1	20050428		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003250159	A1	20040225	AU 2003-250159	20030724
EP 1529031	A1	20050511	EP 2003-784056	20030724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013271	A	20050621	BR 2003-13271	20030724
JP 2005534706	T2	20051117	JP 2004-526766	20030724
US 2004082628	A1	20040429	US 2003-636001	20030807
NO 2005001110	A	20050301	NO 2005-1110	20050301

PRIORITY APPLN. INFO.:

EP 2002-17587	A	20020807
US 2002-432312P	P	20021210
WO 2003-EP8104	W	20030724

OTHER SOURCE(S): MARPAT 140:181465

IT **658683-80-8P 658683-85-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylated arylcycloalkylamines as regulators of transcription of endothelial nitric oxide synthase gene and pharmaceuticals for treatment of cardiovascular disorders)

RN 658683-80-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2,5-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-1-(2-thienylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 658683-85-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2,5-dimethyl-N-[(1R,2S)-2-phenylcyclopropyl]-1-(4-pyridinylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 14 Sep 2003
GI



AB Heterocyclic o-cyclopropyl-carboxanilides (shown as I; e.g. N-[2-(2-isopropylcyclopropyl)phenyl]-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide; Het is a 5- or 6-membered heterocyclic ring containing 1-3 heteroatoms, = O, N and S, the ring being substituted by groups R4, R5 and R6; R1 is H or halo; R2 is H or halo; R3 is (un)substituted C2-12 alkyl, (un)substituted C2-12 alkenyl, (un)substituted C2-12 alkynyl, (un)substituted C3-12 cycloalkyl, (un)substituted Ph or (un)substituted heterocyclyl; and R4, R5 and R6 = H, halo, cyano, nitro, C1-4 haloalkyl, C1-4 alkoxyl (C1-4) alkyl and C1-4 haloalkoxy (C1-4) alkyl, provided that at least one of R4, R5 and R6 is not H) are claimed. I have plant-protective properties and are suitable for protecting plants against infestations by phytopathogenic microorganisms. Three example prepns. are included. To prepare N-[2-(2-isobutylcyclopropyl)phenyl]-1-methyl-4-trifluoromethyl-1H-pyrrole-3-carboxamide, (2-isobutylcyclopropyl)benzene (17.4 g) in Ac2O was nitrated to give a mixture of regioisomers that was hydrogenated over 5 % Pt/C to give a cis/trans mixture of 2-(2-isobutylcyclopropyl)phenylamine (6.38 g) after workup; the anilines (0.35 g) were condensed with 1-methyl-4-trifluoromethylpyrrole-3-carboxylic acid after the latter was reacted with oxalyl chloride in CH2Cl2 for 3 h at room temperature to give 0.52 g of the final product. More than 300 examples of I are tabulated, most without characterization data, and general statements are made as to the activity of some or all of them against Puccinia recondita/wheat (Brownrust on wheat), Podosphaera leucotricha/apple (Powdery mildew on apple), Venturia inaequalis/apple (Scab on apple), Erysiphe graminis/barley (Powdery mildew on barley), Botrytis cinerea/apple (Botrytis on apple fruits), Botrytis cinerea/grape (Botrytis on grapes), Botrytis cinerea/tomato (Botrytis on tomatoes), Pyrenophora teres/barley (Net blotch on barley), and Septoria nodorum/wheat (Septoria leaf spot on wheat). For example, infestation of wheat by brownrust is prevented virtually completely (0-5 % infestation) by N-[2-(2-isopropylcyclopropyl)phenyl]-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide.

ACCESSION NUMBER: 2003:719453 HCAPLUS
DOCUMENT NUMBER: 139:246007
TITLE: Preparation of heterocyclic ortho-cyclopropyl-carboxanilides and their use as fungicides
INVENTOR(S): Ehrenfreund, Josef; Tobler, Hans; Walter, Harald
PATENT ASSIGNEE(S): Syngenta Participations Ag, Switz.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074491	A1	20030912	WO 2003-IB687	20030221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477931	AA	20030912	CA 2003-2477931	20030221
AU 2003208490	A1	20030916	AU 2003-208490	20030221
EP 1480955	A1	20041201	EP 2003-706779	20030221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008230	A	20041228	BR 2003-8230	20030221
JP 2005532271	T2	20051027	JP 2003-572960	20030221
EG 23424	A	20050712	EG 2003-204	20030301
US 2005221989	A1	20051006	US 2005-506918	20050428
PRIORITY APPLN. INFO.:			GB 2002-5127 A	20020305
			GB 2003-705 A	20030113
			WO 2003-IB687 W	20030221

OTHER SOURCE(S): MARPAT 139:246007

IT **599194-97-5**, N-[2-(2-Ethylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599194-98-6**, N-[2-(2-Ethylcyclopropyl)phenyl]-1-(methoxymethyl)-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599194-99-7**, N-[2-(2-Propylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-00-3**, N-[2-(2-Propylcyclopropyl)phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-02-5**, N-[2-[2-(1-Methylethyl)cyclopropyl]phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-03-6**, N-[2-[2-(1-Methylethyl)cyclopropyl]phenyl]-1-methyl-4-(fluoromethyl)-1H-pyrrole-3-carboxamide **599195-04-7**, N-[2-[2-(1-Methylethyl)cyclopropyl]phenyl]-1-methyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide **599195-05-8**, N-[2-[2-(1-Methylethyl)cyclopropyl]phenyl]-1-ethyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide **599195-06-9**, N-[2-[2-(1-Methylethyl)cyclopropyl]phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-07-0**, N-[2-[2-(1-Methylethyl)cyclopropyl]phenyl]-1-ethyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-08-1**, N-[2-[2-(1-Methylethyl)cyclopropyl]phenyl]-1-methyl-4-[(chloro)difluoromethyl]-2-fluoro-1H-pyrrole-3-carboxamide **599195-09-2**, N-[2-(2-Butylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-10-5**, N-[2-(2-Butylcyclopropyl)phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-11-6**, N-[2-(2-Butylcyclopropyl)phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-12-7**, N-[2-(2-Butylcyclopropyl)phenyl]-1-methyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide **599195-14-9**, N-[2-[2-(2-Methylpropyl)cyclopropyl]phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-15-0**, N-[2-[2-(2-Methylpropyl)cyclopropyl]phenyl]-1-methyl-4-(fluoromethyl)-1H-pyrrole-3-carboxamide **599195-16-1**, N-[2-[2-(2-Methylpropyl)cyclopropyl]phenyl]-1-(methoxymethyl)-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-17-2**, N-[2-[2-(2-Methylpropyl)cyclopropyl]phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-18-3**, N-[2-[2-(2-Methylpropyl)cyclopropyl]phenyl]-1-methyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide **599195-20-7**, N-[2-[2-[1,1-Bis(methyl)ethyl]cyclopropyl]phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-21-8**, N-[2-[2-[1,1-Bis(methyl)ethyl]cyclopropyl]phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-22-9**, N-[2-[2-[1,1-Bis(methyl)ethyl]cyclopropyl]phenyl]-1-methyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide **599195-23-0**, N-[2-[2-[1,1-Bis(methyl)ethyl]cyclopropyl]phenyl]-1-methyl-4-[(chloro)difluoromethyl]-1H-pyrrole-3-carboxamide **599195-24-1**, N-[2-(2-Pentylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-25-2**, N-[2-[2-(3-Methylbutyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-26-3**, N-[2-[2-(3-Methylbutyl)cyclopropyl]phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-27-4**, N-[2-(2-Hexylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-29-6**, N-[2-(2-Cyclopropylcyclopropyl)phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-30-9**, N-[2-(2-Cyclopropylcyclopropyl)phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-31-0**, N-[2-(2-Cyclopropylcyclopropyl)phenyl]-1-methyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide **599195-32-1**, N-[2-(2-Cyclobutylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-33-2**, N-[2-(2-Cyclobutylcyclopropyl)phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-35-4**, N-[2-(2-Cyclopentylcyclopropyl)phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-36-5**, N-[2-(2-Cyclopentylcyclopropyl)phenyl]-1-methyl-4-(fluoromethyl)-1H-pyrrole-3-carboxamide **599195-37-6**, N-[2-(2-Cyclopentylcyclopropyl)phenyl]-1-methyl-4-[(chloro)difluoromethyl]-1H-pyrrole-3-carboxamide **599195-38-7**, N-[2-(2-Cyclopentylcyclopropyl)phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-39-8**, N-[2-(2-Cyclopentylcyclopropyl)phenyl]-1-methyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide **599195-41-2**, N-[2-(2-Cyclohexylcyclopropyl)phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-42-3**, N-[2-(2-Cyclohexylcyclopropyl)phenyl]-1-methyl-4-(fluoromethyl)-1H-pyrrole-3-carboxamide **599195-43-4**, N-[2-(2-Cyclohexylcyclopropyl)phenyl]-1-methyl-4-[(chloro)difluoromethyl]-1H-pyrrole-3-carboxamide **599195-44-5**, N-[2-(2,2-Difluoro-3-cyclohexylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-45-6**, N-[2-(2-Cyclohexylcyclopropyl)phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-46-7**, N-[2-(2-Cyclohexylcyclopropyl)phenyl]-1-methyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide **599195-47-8**, N-[2-(2-Cycloheptylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-48-9**, N-[2-(2-Cycloheptylcyclopropyl)phenyl]-1-ethyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-49-0**, N-[2-(2-Cycloheptylcyclopropyl)phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-50-3**, N-[2-(2-Cycloheptylcyclopropyl)phenyl]-1-methyl-4-(fluoromethyl)-1H-pyrrole-3-carboxamide **599195-51-4**, N-[2-(2-Cycloheptylcyclopropyl)phenyl]-1-methyl-4-[(chloro)difluoromethyl]-2-fluoro-1H-pyrrole-3-carboxamide **599195-52-5**, N-[2-(2-Cycloheptylcyclopropyl)phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-53-6**, N-[2-(2-Cycloheptylcyclopropyl)phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-54-7**, N-[2-(2-Cyclooctylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-55-8**, N-[2-(2-Cyclooctylcyclopropyl)phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-56-9**, N-[2-(2-Phenylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-57-0**, N-[2-(2-Phenylcyclopropyl)phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-58-1**, N-[2-(2-Phenylcyclopropyl)phenyl]-1-methyl-4-(fluoromethyl)-1H-pyrrole-3-carboxamide **599195-59-2**, N-[2-(2-Phenylcyclopropyl)phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-60-5**, N-[2-(2-Phenylcyclopropyl)phenyl]-1-methyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide **599195-62-7**, N-[2-[2-(4-Fluorophenyl)cyclopropyl]phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-64-9**, N-[2-[2-(4-Chlorophenyl)cyclopropyl]phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-65-0**, N-[2-[2-(4-Bromophenyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-66-1**, N-[2-[2-(4-Bromophenyl)cyclopropyl]phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-67-2**, N-[2-[2-(2-Thienyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-68-3**, N-[2-[2-(3-Thienyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-69-4**, N-[2-[2-(2-Furyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide **599195-71-8**, N-[2-[2-(1-Methylcyclopropyl)cyclopropyl]phenyl]-1-methyl-4-(difluoromethyl)-1H-pyrrole-3-carboxamide **599195-72-9**, N-[2-[2-(1-Methylcyclopropyl)cyclopropyl]phenyl]-1-methyl-4-methyl-2-fluoro-1H-pyrrole-3-carboxamide **599195-73-0**, N-[2-[2-(1-Methylcyclopropyl)cyclopropyl]phenyl]-1-methyl-4-methyl-2-chloro-1H-pyrrole-3-carboxamide
RL: AGR (Agricultural use); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(prepn. of heterocyclic ortho-cyclopropyl-carboxanilides and their use as fungicides)

RN 599194-97-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-ethylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599194-98-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-ethylcyclopropyl)phenyl]-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599194-99-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(2-propylcyclopropyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-00-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-(2-propylcyclopropyl)phenyl]- (9CI) (CA INDEX NAME)



RN 599195-02-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-03-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



RN 599195-04-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[2-[2-(1-methylethyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-08-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-2-fluoro-1-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



RN 599195-09-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-butylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-10-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-butylcyclopropyl)phenyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 599195-05-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1-ethyl-4-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



RN 599195-06-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[2-[2-(1-methylethyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



RN 599195-07-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-ethyl-2-fluoro-4-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-11-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-butylcyclopropyl)phenyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 599195-12-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-butylcyclopropyl)phenyl]-2-chloro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 599195-14-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-[2-(2-

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methylpropyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



RN 599195-15-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[2-[2-(2-methylpropyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



RN 599195-16-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(methoxymethyl)-N-[2-[2-(2-methylpropyl)cyclopropyl]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-17-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[2-[2-(2-methylpropyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



RN 599195-18-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[2-[2-(2-methylpropyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 599195-20-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[2-[2-(1,1-dimethylethyl)cyclopropyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-21-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(1,1-dimethylethyl)cyclopropyl]phenyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 599195-22-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[2-[2-(1,1-dimethylethyl)cyclopropyl]phenyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-23-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[2-[2-(1,1-dimethylethyl)cyclopropyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-24-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(2-pentylcyclopropyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-25-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(3-methylbutyl)cyclopropyl]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)



RN 599195-26-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-[2-(3-methylbutyl)cyclopropyl]phenyl]- (9CI) (CA INDEX NAME)



RN 599195-27-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-hexylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-29-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-bicyclopropyl]-2-ylphenyl)-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-30-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-bicyclopropyl]-2-ylphenyl)-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 599195-31-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-bicyclopropyl]-2-ylphenyl)-2-chloro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 599195-32-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclobutylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-33-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclobutylcyclopropyl)phenyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-35-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclopentylcyclopropyl)phenyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-36-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclopentylcyclopropyl)phenyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-37-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[2-(2-cyclopentylcyclopropyl)phenyl]-1-methyl- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-38-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclopentylcyclopropyl)phenyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 599195-39-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[2-(2-cyclopentylcyclopropyl)phenyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-41-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclohexylcyclopropyl)phenyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-42-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclohexylcyclopropyl)phenyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 599195-43-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[2-(2-cyclohexylcyclopropyl)phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-44-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3-cyclohexyl-2,2-difluorocyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-45-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclohexylcyclopropyl)phenyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-46-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[2-(2-cyclohexylcyclopropyl)phenyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 599195-47-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-48-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)phenyl]-1-ethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-49-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)phenyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-50-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)phenyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-51-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[2-(2-cycloheptylcyclopropyl)phenyl]-2-fluoro-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-52-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)phenyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 599195-53-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[2-(2-cycloheptylcyclopropyl)phenyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 599195-54-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclooctylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-55-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclooctylcyclopropyl)phenyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-56-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(2-phenylcyclopropyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-57-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-(2-phenylcyclopropyl)phenyl]- (9CI) (CA INDEX NAME)



RN 599195-58-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[2-(2-phenylcyclopropyl)phenyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-59-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[2-(2-phenylcyclopropyl)phenyl]- (9CI) (CA INDEX NAME)



RN 599195-60-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[2-(2-phenylcyclopropyl)phenyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-62-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[2-[2-(4-fluorophenyl)cyclopropyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-64-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(4-chlorophenyl)cyclopropyl]phenyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 599195-65-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(4-bromophenyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-66-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(4-bromophenyl)cyclopropyl]phenyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 599195-67-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(2-thienyl)cyclopropyl]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-68-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(3-thienyl)cyclopropyl]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-69-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(2-furanyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-71-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-(1'-methyl[1,1'-bicyclopropyl]-2-yl)phenyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-72-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[2-(1'-methyl[1,1'-bicyclopropyl]-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 599195-73-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[2-(1'-methyl[1,1'-bicyclopropyl]-2-yl)phenyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-13-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(2-methylpropyl)cyclopropyl]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-19-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(1,1-dimethylethyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-28-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-bicyclopropyl]-2-ylphenyl)-1-methyl-4-

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 599195-01-4P, N-[2-[2-(1-Methylethyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599195-13-8P, N-[2-[2-(2-Methylpropyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599195-19-4P, N-[2-[2-[1,1-Bis(methyl)ethyl]cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599195-28-5P, N-[2-(2-Cyclopropylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599195-34-3P, N-[2-(2-Cyclopentylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599195-40-1P, N-[2-(2-Cyclohexylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599195-61-6P, N-[2-[cis-2-(4-Fluorophenyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599195-63-8P, N-[2-[cis-2-(4-Chlorophenyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599195-70-7P, N-[2-[2-(1-Methylcyclopropyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599195-74-1P, N-[2-[cis-2-(1-Methylcyclopropyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-2-chloro-1H-pyrrole-3-carboxamide 599197-47-4P, N-[2-[trans-2-(4-Fluorophenyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599197-48-5P, N-[2-[trans-2-(4-Chlorophenyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide 599197-49-6P, N-[2-[trans-2-(1-Methylcyclopropyl)cyclopropyl]phenyl]-1-methyl-4-(trifluoromethyl)-2-chloro-1H-pyrrole-3-carboxamide
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic ortho-cyclopropyl-carboxanilides and their use as fungicides)

RN 599195-01-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-34-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclopentylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-40-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclohexylcyclopropyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 599195-61-6 HCAPLUS

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[2-[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]phen yl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 599195-63-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(1R,2S)-2-(4-chlorophenyl)cyclopropyl]phen yl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 599195-70-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(1'-methyl[1,1'-bicyclopropyl]-2-yl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 599197-48-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(1R,2R)-2-(4-chlorophenyl)cyclopropyl]phen yl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 599197-49-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1-methyl-N-[2-[(1R,2R)-1'-methyl[1,1'-bicyclopropyl]-2-yl]phenyl]-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 599195-74-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1-methyl-N-[2-[(1R,2S)-1'-methyl[1,1'-bicyclopropyl]-2-yl]phenyl]-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 599197-47-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(1R,2R)-2-(4-fluorophenyl)cyclopropyl]phen yl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 23 Aug 2002
GI



I

AB Title compds. I [R1 = CF3, CF2H, CFH2; R2-3 = H, F; R4 = H, F, Cl, Br, Me, CF3, OCF3, SCF3] were prepared For instance, 1-methyl-4-trifluoromethyl-1H-pyrrole-3-carboxylic acid (preparation given) was converted to the corresponding acid chloride (CH2Cl2, ClCOCOCl, DMF) and subsequently reacted with 2-(4'-bromophenyl)aniline to afford I [R1 = CF3; R2-4 = H; II]. Administration of a formulation of II (0.02%) to a one week old wheat plant (Arina) followed by innoculation with Puccinia recondita (brownrust) and incubation resulted in <5% infestation after 8 days at 20° and 60% relative humidity. I are suitable for protecting plants against infestations by phytopathogenic microorganisms.

ACCESSION NUMBER: 2002:637651 HCAPLUS
DOCUMENT NUMBER: 137:169413
TITLE: Preparation of pyrrolecarboxamides for use as fungicides
INVENTOR(S): Walter, Harald
PATENT ASSIGNEE(S): Syngenta Participations Ag, Switz.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064562	A1	20020822	WO 2002-EP1344	20020208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM; AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EG 23036	A	20040131	EG 2002-149	20020205
CA 2436271	AA	20020822	CA 2002-2436271	20020208
EP 1360176	A1	20031112	EP 2002-719787	20020208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007128	A	20040330	BR 2002-7128	20020208
CN 1491212	A	20040421	CN 2002-804755	20020208
JP 2004528297	T2	20040916	JP 2002-564495	20020208

L13 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

ZA 2003005934 A 20040830 ZA 2003-5934 20030731
US 2004082477 A1 20040429 US 2003-467643 20031126
PRIORITY APPLN. INFO.: GB 2001-3258 A 20010209
WO 2002-EP1344 W 20020208
OTHER SOURCE(S): CASREACT 137:169413; MARPAT 137:169413

IT 448235-93-6P 448235-94-7P 448235-95-8P
448235-96-9P 448235-97-0P 448235-98-1P
448235-99-2P 448236-00-8P 448236-01-9P
448236-02-0P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fungicide; preparation of pyrrolecarboxamides for use as fungicides)

RN 448235-93-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo[1,1'-biphenyl]-2-yl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 448235-94-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo[1,1'-biphenyl]-2-yl)-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 448235-95-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo[1,1'-biphenyl]-2-yl)-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)

L13 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 448235-98-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo[1,1'-biphenyl]-2-yl)-2-fluoro-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 448235-99-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo-3-fluoro[1,1'-biphenyl]-2-yl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 448236-00-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo-3-fluoro[1,1'-biphenyl]-2-yl)-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)

L13 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 448235-96-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo[1,1'-biphenyl]-2-yl)-2-fluoro-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 448235-97-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo[1,1'-biphenyl]-2-yl)-4-(difluoromethyl)-2-fluoro-1-methyl- (9CI) (CA INDEX NAME)

L13 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 448236-01-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo-3-fluoro[1,1'-biphenyl]-2-yl)-2-fluoro-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 448236-02-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-bromo-3-fluoro[1,1'-biphenyl]-2-yl)-4-(difluoromethyl)-2-fluoro-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 May 2002
GI



AB The title compds. [I; X = O, S; R1 = CF3, CF2H, CFH2; R2 = alkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl; R3 = H, Me, CF3, F; Q = substituted Ph, 2-thienyl, 3-thienyl] which have plant-protecting properties and are suitable for protecting plants against infestation by phytopathogenic microorganisms, were prepared Thus, treating 1-methyl-4-trifluoromethylpyrrole-3-carboxylic acid with oxalyl chloride in the presence of a catalytic amount of DMF in CH2Cl2 followed by addition of the resulting acid chloride to a solution of 2-(1,3-dimethylbutyl)phenylamine and Et3N in CH2Cl2 afforded II. Compds. I showed good activity (< 20% infestation) against Puccinia recondita (brown rust) on wheat.

ACCESSION NUMBER: 2002:368451 HCAPLUS
DOCUMENT NUMBER: 136:369602
TITLE: Preparation of pyrrolecarboxamides and pyrrolecarbothioamides as agrochemical fungicides
INVENTOR(S): Walter, Harald
PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038542	A1	20020516	WO 2001-EP12830	20011106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2426033	AA	20020516	CA 2001-2426033	20011106
AU 2002023668	A5	20020521	AU 2002-23668	20011106
EP 1341757	A1	20030910	EP 2001-993599	20011106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

BR 2001015200	A	20040217	BR 2001-15200	20011106
EG 23122	A	20040428	EG 2001-1173	20011106
JP 2004513163	T2	20040430	JP 2002-541078	20011106
US 2005119130	A1	20050602	US 2003-416219	20011106
ZA 2003003012	A	20040520	ZA 2003-3012	20030416

PRIORITY APPLN. INFO.:

GB 2000-27284	A	20001108
GB 2000-30268	A	20001212
WO 2001-EP12830	W	20011106

OTHER SOURCE(S): MARPAT 136:369602
IT 424832-15-5P 424832-16-6P 424832-17-7P
424832-18-8P 424832-19-9P 424832-20-2P
424832-21-3P 424832-22-4P 424832-23-5P
424832-24-6P 424832-25-7P 424832-26-8P
424832-27-9P 424832-28-0P 424832-29-1P
424832-30-4P 424832-31-5P 424832-32-6P
424832-33-7P 424832-34-8P 424832-35-9P
424832-36-0P 424832-37-1P 424832-38-2P
424832-39-3P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolecarboxamides and pyrrolecarbothioamides as agrochem. fungicides)
RN 424832-15-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.1]hepta-2,5-dien-2-ylphenyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-16-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.1]hept-2-en-2-ylphenyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-17-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.1]hept-5-en-2-ylphenyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 424832-18-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylphenyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-19-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl-6-fluorophenyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-20-2 HCAPLUS

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[2-[(1R,2S,4S)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-21-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylphenyl]-1-(methoxymethyl)-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-22-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylphenyl]-4-(difluoromethyl)-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 424832-26-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-ylphenyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-27-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-ylphenyl)-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-28-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-4-fluorophenyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 424832-23-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]octa-2,5-dien-2-ylphenyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-24-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-en-2-ylphenyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-25-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.2]oct-5-en-2-ylphenyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 424832-29-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-4-fluorophenyl)-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-30-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-ylphenyl)-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 424832-31-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.1]hept-5-en-2-ylphenyl]-2-fluoro-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 424832-32-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylphenyl]-2-fluoro-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-33-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.1]hept-5-en-2-ylphenyl]-2-fluoro-1-(methoxymethyl)-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 424832-36-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-ylphenyl)-2-fluoro-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-37-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-ylphenyl)-2-fluoro-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-38-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylphenyl]-1,2-dimethyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 424832-34-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylphenyl]-2-fluoro-1-(methoxymethyl)-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-35-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.2]oct-5-en-2-ylphenyl]-2-fluoro-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 424832-39-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-ylphenyl)-1,2-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 01 Feb 2002
GI



AB Title compds. [I; R = H, (halo)alkyl, cycloalkyl; Z = H, (halo)alkyl; X, Y = halo, NO2, cyano, OH, CO2H, cycloalkyl, alkoxycarbonyl, alkoxyimidoalkyl, (halo-substituted) alkyl, alkoxy, alkylthio, alkenyloxy, alkynyloxy, alkylsulfonyl, alkylsulfinyl; m = 0-3; n = 0-4; A = (substituted) 1H-pyrazol-4-yl, 2- or 3-thienyl, Ph, 3-pyridinyl, 3-pyranyl, 1,4-oxathiin-3-yl, 2- or 3-thiopyranyl, 3-pyrrolyl, 3- or 2-furanyl, 5- or 4-thiazolyl, 4-isothiazolyl, 5-isoxazolyl, 2-pyrazinyl], were prepared Thus, a mixture of 2-(4-methoxyiminomethylphenyl)benzenamine (preparation given) and Et3N in PhMe was stirred with 2-methyl-4-trifluoromethylthiazole-5-carbonyl chloride at room temperature followed by stirring for 2 h at 50° to give 74% N-[2-(4-methoxyimidomethylphenyl)phenyl]-2-methyl-4-trifluoromethylthiazole-5-carboxamide. Several I at 100 ppm gave 77-100% control of Podosphaera leucotricha on apple.

ACCESSION NUMBER: 2002:90017 HCAPLUS
DOCUMENT NUMBER: 136:151158
TITLE: Preparation of N-biphenylcarboxamides as bactericides
INVENTOR(S): Elbe, Hans-Ludwig; Rieck, Heiko; Dunkel, Ralf; Wachendorff-Neumann, Ulrike; Mauler-Machnik, Astrid; Kuck, Karl-Heinz; Kugler, Martin; Jaetsch, Thomas
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008197	A1	20020131	WO 2001-EP7981	20010711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10122447	A1	20020418	DE 2001-10122447	20010509
EP 1305292	A1	20030502	EP 2001-956525	20010711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012676	A	20030624	BR 2001-12676	20010711
JP 2004504383	T2	20040212	JP 2002-514103	20010711
ZA 2003000633	A	20040212	ZA 2003-633	20030123
US 2004039043	A1	20040226	US 2003-333598	20030506
PRIORITY APPLN. INFO.:			DE 2000-10035857 A	20000724
			DE 2001-10122447 A	20010509
			WO 2001-EP7981 W	20010711

OTHER SOURCE(S): MARPAT 136:151158
IT 393820-64-9P 393820-67-2P 393821-62-0P 393821-83-5P 393821-85-7P 393821-86-8P 393821-87-9P 393821-90-4P 393822-21-4P 393822-42-9P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-biphenylcarboxamides as bactericides)

RN 393820-64-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[(methoxyimino)methyl][1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 393820-67-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[(methoxyimino)methyl][1,1'-biphenyl]-2-yl]-1,4-dimethyl- (9CI) (CA INDEX NAME)

L13 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 393821-62-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[(methoxyimino)methyl][1,1'-biphenyl]-2-yl]-1-methyl-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 393821-83-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[1-(methoxyimino)ethyl][1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 393821-85-7 HCAPLUS

L13 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[4'-[1-(methoxyimino)ethyl][1,1'-biphenyl]-2-yl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 393821-86-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[(ethoxyimino)methyl][1,1'-biphenyl]-2-yl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 393821-87-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[1-(methoxyimino)ethyl][1,1'-biphenyl]-2-yl]-1-methyl-4-(1-methylethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 393821-90-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[(ethoxyimino)methyl][1,1'-biphenyl]-2-yl]-1-methyl-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 393822-21-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4'-[(ethoxyimino)methyl][1,1'-biphenyl]-2-yl]-1,4-dimethyl- (9CI) (CA INDEX NAME)

L13 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 393822-42-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4'-[[(1-methylethoxy)imino]methyl][1,1'-biphenyl]-2-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 17 Aug 2001
GI



AB The title compds. [I; A, B = C, N so that ring X = pyrrole, pyrazole or imidazole (wherein when A = N, the group CONR1R2 is attached to atom C-3 and R5 does not exist; and when A = C, one of CONR1R2 and R5 is attached to A and the other to atom C-3; and when B = C, two R4 groups attached to B and atom C-5, resp., form a fused 6-membered heteroaryl); f = 0-1; g = 1-2; R1, R2 = H, alkyl, heterocycloalkyl, etc.; R2 together with R1 or R5 forms a 5-6 membered heterocyclo; R3 = H, alkyl, aryl, etc.; R4 is attached to atom C-5 and optionally B and is H, alkyl, aryl, etc.; R5 is attached to A or atom C-3 and is H, alkyl, aryl, etc.; R5 together with R2 forms a heterocyclo], useful as cannabinoid receptor modulators (no data given) for treating respiratory and non-respiratory leukocyte-activation associated diseases, were prepared Thus, reacting the acid chloride II [X = Cl] (multi-step synthesis given) with 2,2,6,6-tetramethylcyclohexylamine afforded the pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamide II [X = 2,2,6,6-tetramethylcyclohexylamino].

ACCESSION NUMBER: 2001:597958 HCAPLUS
DOCUMENT NUMBER: 135:166827
TITLE: Preparation of 1H-indole-3-carboxamides, 1H-indazole-3-carboxamides, 1H-pyrido[4,3-b]indol-1-ones and pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamides as cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
INVENTOR(S): Leftheris, Katerina; Zhao, Rulin; Chen, Bang-Chi; Kiener, Peter; Wu, Hong; Pandit, Chennagiri R.; Wrobleski, Stephen; Chen, Ping; Hynes, John, Jr.; Longphre, Malinda; Norris, Derek J.; Spergel, Steven; Tokarski, John
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; et al.
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058869	A2	20010816	WO 2001-US4131	20010208
WO 2001058869	A3	20020124		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

L13 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2399791	AA	20010816	CA 2001-2399791	20010208
AU 2001034958	A5	20010820	AU 2001-34958	20010208
EP 1254115	A2	20021106	EP 2001-907144	20010208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502642	T2	20040129	JP 2001-558420	20010208
PRIORITY APPLN. INFO.:			US 2000-181818P	P 20000211
			WO 2001-US4131	W 20010208

OTHER SOURCE(S): MARPAT 135:166827
IT 354569-58-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-indole-3-carboxamides, 1H-indazole-3-carboxamides, 1H-pyrido[4,3-b]indol-1-ones and pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamides as cannabinoid receptor modulators for treating respiratory and non-respiratory diseases)
RN 354569-58-7 HCAPLUS
CN 1H-Indole-3-carboxamide, 5-fluoro-7-methoxy-2-methyl-1-[2-(4-morpholinyl)ethyl]-N-[(1S,2S)-2-phenylcyclopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 27 Jul 2001
GI



I

AB The title compds. [I; X = O, S; R1 = alkyl, cycloalkyl, halo; R2 = H, alkyl, alkoxy, etc.; R3 = alkyl; A = (un)substituted ortho-substituted (hetero)aryl, bicyclo(hetero)aryl] which have plant-protective properties and are suitable for protecting plants against infestations by phytopathogenic microorganisms, were prepared Thus, methylation of Me 4-methylpyrrole-3-carboxylate followed by hydrolysis of the resulting ester, and reaction of 1,4-dimethylpyrrole-3-carboxylic acid with 2-(4'-fluorophenyl)aniline afforded I [X = O; R1, R3 = Me; R2 = H; A = 4'-fluorobiphenyl-2-yl] which showed strong efficacy against Puccinia recondita on wheat (< 20% infestation).

ACCESSION NUMBER: 2001:545661 HCAPLUS
DOCUMENT NUMBER: 135:137397
TITLE: Preparation of pyrrolecarboxamides and pyrrolethioamides as fungicides
INVENTOR(S): Walter, Harald; Schneider, Hermann
PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053259	A1	20010726	WO 2001-EP592	20010119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2397008	AA	20010726	CA 2001-2397008	20010119
BR 2001007738	A	20021022	BR 2001-7738	20010119
EP 1252140	A1	20021030	EP 2001-907468	20010119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003520269	T2	20030702	JP 2001-553263	20010119
AU 772635	B2	20040506	AU 2001-35433	20010119
ZA 2002005641	A	20031103	ZA 2002-5641	20020715

US 2004049035	A1	20040311	US 2002-181702	20021008
US 6806286	B2	20041019		
US 2004106521	A1	20040603	US 2003-680346	20031007

PRIORITY APPLN. INFO.:

GB 2000-1447	A	20000121
WO 2001-EP592	W	20010119
US 2002-181702	A3	20021008

OTHER SOURCE(S): MARPAT 135:137397
IT 351416-52-9P 351416-53-0P 351416-54-1P 351416-55-2P 351416-57-4P 351416-59-6P 351416-60-9P 351416-61-0P 351416-62-1P 351416-63-2P 351416-64-3P 351416-66-5P 351416-67-6P 351416-68-7P 351416-69-8P 351416-70-1P 351416-71-2P 351416-72-3P 351416-73-4P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolecarboxamides and pyrrolethioamides as fungicides)
RN 351416-52-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1-cyclohexen-1-yl)phenyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 351416-53-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-cyclohexylphenyl)-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 351416-54-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 351416-55-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-fluoro[1,1'-biphenyl]-2-yl)-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 351416-57-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 351416-59-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1-cyclohexen-1-yl)phenyl]-1-methyl-4-(pentafluoroethyl)- (9CI) (CA INDEX NAME)



RN 351416-60-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-cyclohexylphenyl)-1-methyl-4-(pentafluoroethyl)- (9CI) (CA INDEX NAME)



RN 351416-61-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-1-methyl-4-

L13 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(pentafluoroethyl)- (9CI) (CA INDEX NAME)



RN 351416-62-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-fluoro[1,1'-biphenyl]-2-yl)-1-methyl-4-(pentafluoroethyl)- (9CI) (CA INDEX NAME)



RN 351416-63-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-cyclohexylphenyl)-4-cyclopropyl-1-methyl- (9CI) (CA INDEX NAME)

L13 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 351416-64-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-4-cyclopropyl-1-methyl- (9CI) (CA INDEX NAME)



RN 351416-66-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-4-ethyl-1-methyl- (9CI) (CA INDEX NAME)



L13 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 351416-67-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-ethyl-N-(4'-fluoro[1,1'-biphenyl]-2-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 351416-68-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-1,4-diethyl- (9CI) (CA INDEX NAME)



RN 351416-69-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,4-diethyl-N-(4'-fluoro[1,1'-biphenyl]-2-yl)- (9CI) (CA INDEX NAME)

L13 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 351416-70-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-1-methyl-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 351416-71-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-fluoro[1,1'-biphenyl]-2-yl)-1-methyl-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 351416-72-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-1-ethyl-4-(1-methylethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 351416-73-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-ethyl-N-(4'-fluoro[1,1'-biphenyl]-2-yl)-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 2004171490 A1 20040902 US 2004-785836 20040224
PRIORITY APPLN. INFO.: GB 1999-30750 A 19991229
WO 2000-EP11196 W 20001111
US 2002-169281 A3 20021008

OTHER SOURCE(S): MARPAT 135:92539
IT 349483-58-5P 349483-59-6P 349483-73-4P
349483-74-5P 349483-75-6P 349483-76-7P
349483-91-6P 349483-92-7P 349483-93-8P
349483-94-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of trifluoromethylpyrrole carboxamides and trifluoromethylpyrrolethioamides as fungicides)
RN 349483-58-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(4-methylcyclohexyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 349483-59-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-ethylcyclohexyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 349483-73-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(3-methylcyclopentyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Jul 2001
GI



I

AB The title compds. [I; X = O, S; R1 = H, alkyl, halo; R2 = alkyl; A = ortho-substituted aryl, ortho-substituted heteroaryl, bicycloaryl, bicycloheteroaryl] which have plant-protective properties and are suitable for protecting plants against infestations by phytopathogenic microorganisms, were prepared E.g., a multi-step synthesis of I [R1 = H; R2 = Me; X = O; A = 4-(4-chlorophenyl)pyridin-3-yl] which showed strong efficacy against Erysiphe graminis on barley, was given.

ACCESSION NUMBER: 2001:507677 HCAPLUS
DOCUMENT NUMBER: 135:92539
TITLE: Preparation of trifluoromethylpyrrole carboxamides and trifluoromethylpyrrolethioamides as fungicides
INVENTOR(S): Walter, Harald; Trah, Stephan; Schneider, Hermann
PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049664	A1	20010712	WO 2000-EP11196	20001111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395267	AA	20010712	CA 2000-2395267	20001111
BR 2000016871	A	20021008	BR 2000-16871	20001111
EP 1252139	A1	20021030	EP 2000-985016	20001111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519212	T2	20030617	JP 2001-550204	20001111
EG 22599	A	20030430	EG 2000-1588	20001224
ZA 2002004874	A	20030918	ZA 2002-4874	20020618
US 6699818	B1	20040302	US 2002-169281	20021008

L13 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 349483-74-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(methoxymethyl)-N-[2-(3-methylcyclopentyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 349483-75-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(3-methylcyclohexyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 349483-76-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(methoxymethyl)-N-[2-(3-methylcyclohexyl)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 349483-91-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3-ethylcyclohexyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 349483-92-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[2-[3-(trifluoromethyl)cyclohexyl]phenyl]- (9CI) (CA INDEX NAME)



L13 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 25 Feb 2000
GI



I

AB Title compds. I (R1 = H, halo, alkyl, haloalkyl; R2 = alkyl, haloalkyl, alkoxyalkyl, cyano, alkylsulfonyl, arylsulfonyl, etc.; A = substituted Ph, substituted 3-thienyl, substituted 4-indanyl) were prepared as plant protectants. Thus, 1.9 g 1-methyl-4-(trifluoromethyl)pyrrole-3-carboxylic acid, obtained from Et 4,4,4-trifluorocrotonate, tosylmethyl isocyanide, and MeI, and 0.9 mL oxalyl chloride in 20 mL CH2Cl2 was stirred at room temperature in the presence of a catalytic amount of DMF, the solvent was evaporated under reduced pressure to give a crystalline solid, and the solid was added to a solution of 1.7 g of 2-biphenylamine and 4.2 mL Et3N in 20 mL CH2Cl2 at 0°, and the reaction mixture was stirred for 2 h at room temperature to give I (R1 = H, R2 = Me, A = 2-biphenylyl). Application of this compound on apples, grapes, and tomatoes resulted in <10% infestation by Botrytis cinerea.

ACCESSION NUMBER: 2000:133660 HCAPLUS
DOCUMENT NUMBER: 132:166122
TITLE: (Trifluoromethyl)pyrrolecarboxamides
INVENTOR(S): Eberle, Martin; Walter, Harald
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009482	A1	20000224	WO 1999-EP5837	19990810
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 576831	B	20040221	TW 1999-88107745	19990513
AU 9955138	A1	20000306	AU 1999-55138	19990810
AU 756140	B2	20030102		
BR 9912962	A	20010508	BR 1999-12962	19990810
EP 1105375	A1	20010613	EP 1999-941573	19990810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100478	T2	20010621	TR 2001-200100478	19990810
JP 2002522526	T2	20020723	JP 2000-564936	19990810

L13 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 349483-93-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3-ethylcyclopentyl)phenyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 349483-94-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[2-[3-(trifluoromethyl)cyclopentyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RU 2264388	C2	20051120	RU 2001-105955	19990810
US 2002019541	A1	20020214	US 2001-780897	20010209
US 6365620	B2	20020402		

PRIORITY APPLN. INFO.: GB 1998-17548 A 19980812
WO 1999-EP5837 W 19990810
OTHER SOURCE(S): MARPAT 132:166122
IT 258510-84-8P 258510-85-9P 258510-86-0P 258510-87-1P 258510-92-8P 258510-93-9P 258510-95-1P 258510-98-4P 258510-99-5P 258511-00-1P 258511-01-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
((trifluoromethyl)pyrrolecarboxamides as plant protectants)
RN 258510-84-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[1,1'-biphenyl]-2-yl-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258510-85-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[1,1'-biphenyl]-2-yl-1,5-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258510-86-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 258510-87-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-fluoro[1,1'-biphenyl]-2-yl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258510-92-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[1,1':4',1''-terphenyl]-2-yl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 258510-99-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-dimethyl-N-[1,1':4',1''-terphenyl]-2-yl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258511-00-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3',5'-difluoro[1,1'-biphenyl]-2-yl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258511-01-2 HCAPLUS

L13 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 258510-93-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3',5'-dichloro[1,1'-biphenyl]-2-yl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258510-95-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 258510-98-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4'-chloro[1,1'-biphenyl]-2-yl)-1,5-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-(3'-chloro-5'-fluoro[1,1'-biphenyl]-2-yl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 05 Aug 1998
GI



I



II

AB The invention provides substituted pyridylpyrroles I [Pyr = pyridine nucleus; R1 = H, (un)substituted alkyl, heterocyclyl, aryl, etc.; R2 = (un)substituted alkyl, (hetero)aryl, heterocyclyl, etc.; R3 = H, halo, alkyl, acyl, etc.; R4 = acyl, aryl, heterocyclyl, alkoxycarbonyl, etc.; R5 = halo, (un)substituted (hetero)aryl, etc.], as well as comprns. containing such compds. and methods of treatment. I are glucagon antagonists and inhibitors of the biosynthesis and action of TNF-α, IL-1, IL-8, and other cytokines. The compds. block the action of glucagon at its receptors, and thereby decrease the levels of plasma glucose, making the compds. useful as antidiabetic agents. For instance, 4-FC6H4COMe(OMe) was condensed with 4-[[(tert-butyldimethylsilyl)oxy]methyl]pyridine, and the product ketone was cyclized with 4-(MeS)C6H4COMe using KCN and then NH4OAc in refluxing aqueous EtOH, to give title compound II. In a glucagon receptor binding assay, I typically showed IC50 < 2.0 μM.

ACCESSION NUMBER: 1998:487827 HCAPLUS
DOCUMENT NUMBER: 129:122578
TITLE: Preparation of pyridylpyrroles and analogs as cytokine inhibitors and glucagon antagonists
INVENTOR(S): De Laszlo, Stephen E.; Chang, Linda L.; Kim, Dooseop; Mantlo, Nathan B.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 59 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5776954	A	19980707	US 1996-742428	19961030
PRIORITY APPLN. INFO.:			US 1996-742428	19961030

OTHER SOURCE(S): MARPAT 129:122578
IT 191030-88-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridylpyrroles and analogs as cytokine inhibitors and glucagon antagonists)
RN 191030-88-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[1,1'-biphenyl]-2-yl-5-(4-chlorophenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Jul 1997
GI



I

AB Title compds. [I; R1 = H, alkyl, heterocyclyl, aryl, etc.; R2 = alkyl, (hetero)aryl, heterocyclyl, etc.; R3 = H, halo, alkyl, aryl, etc.; R4 = aryl, heterocyclyl, alkoxycarbonyl, etc.; R5 = (un)substituted heteroaryl] were prepared Thus, 4-FC6H4CH:CHCOC6H4Cl-4 was condensed with 2-pyridinecarboxaldehyde and the product cyclocondensed with NH4OAc to give I (R1 = R3 = H, R2 = C6H4Cl-4, R4 = C6H4F-4, R5 = 2-pyridyl). Data for biol. activity of I were given.

ACCESSION NUMBER: 1997:433593 HCAPLUS
DOCUMENT NUMBER: 127:50543
TITLE: Preparation of pyridylpyrroles and analogs as cytokine inhibitors and glucagon antagonists
INVENTOR(S): De Laszlo, Stephen E.; Chang, Linda L.; Kim, Dooseop; Mantlo, Nathan B.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9716442	A1	19970509	WO 1996-US18539	19961030
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2234701	AA	19970509	CA 1996-2234701	19961030
AU 9711208	A1	19970522	AU 1997-11208	19961030
AU 702887	B2	19990311		
EP 859771	A1	19980826	EP 1996-942022	19961030
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11514651	T2	19991214	JP 1996-517642	19961030
PRIORITY APPLN. INFO.:			US 1995-7100P	P 19951031
			GB 1996-5158	A 19960312
			US 1996-15565P	P 19960418
			GB 1996-12062	A 19960610
			WO 1996-US18539	W 19961030

OTHER SOURCE(S): MARPAT 127:50543
IT 191030-88-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

L13 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridylpyrroles and analogs as cytokine inhibitors and glucagon antagonists)
RN 191030-88-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[1,1'-biphenyl]-2-yl-5-(4-chlorophenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



10636001RTR

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	74.07	596.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.50	-12.00

STN INTERNATIONAL LOGOFF AT 14:43:54 ON 01 MAR 2006